var title_f36_40_37504="First branchial arch";
var content_f36_40_37504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76109&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First branchial arch derivatives",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 364px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFsAVMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAoqO4nitoJJ7iVIoY1LPJIwVVA6kk9BXJ/8ACbpqbeX4P0y617PH2tD5FkPfz2GHH/XMPQB2FNkdI0Z5GVEUZZmOAB7muRXQ/E+qHfrniP8As+I/8ueiRKg+jTShnb6qI/pUkfw98MmRZb/Tjq04OfM1aeS9IPqPNZgPwAx2oAkuvH/hS3meEa7Z3Nwn3oLJjdSr9UiDN+lR/wDCZST/APIL8L+Jb4dibRbQH/wIeMj8q6a2traxtxFaww28CchI1CKPwHFYOoeOvC2nzmC58Qab9pHW3jnWSX/vhct+lAEH9seLZv8Aj28KWkXp9u1YR/n5ccn9aDqHjZeW8OeHmUdRHrsxb8M2gH6imnx1ZSZ+waT4jvfePSJ41PXo0qoD+B707/hKdWk/49/BHiBvR5JbKNfxzcbv/HaAD+3/ABHD/wAfPgy7lx/z5ahbyZ+nmNH/AE/CkPjQw4+3eGvE1r6/6D9ox/34Z/8AP1FO/wCEi1//AKErUv8AwNtP/jtJ/wAJXqUePtfgvxHCvd1a0mHvgJOWI/4D/hQAh+InhaM4vdTOnev9pW0tnj6+cq479fSt/S9X03VovN0rULO+i/v20yyj81Jrnz8QNCg41Q6jpJ7nUdPnt4x/20ZPLP4MaP7C8FeLovttvaaNqR/hvbIoZFz/AHZozuH4GgDraK47+wfEmjj/AIp7X/t1uvSz1xTL+C3C4kH1cSGlbxpLpgA8VaDqWlAfeuoEN7a/XzIwWUe7olAHYUVR0fV9N1qzW70e/tb61PAltpVkXPpkHr7VeoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK5nX/Fkdlf/ANkaNaSavrzKG+xwttWFT0eeTpEv1yx/hVqAOhuriG0t5Li7mjgt4lLPJIwVUA6kk8AVyK+K7/X38vwXp32i2P8AzGL4NHafWNeHn/4DtQ/36da+D5NTuYr/AMa3SatdRtviskUrY2x7bYz/AKxh/fkye4C9K7EDAwOlAHIW3ge2uZ0u/Fd5P4ivUbeguwFtoW7eXbj5Bjszbm/2q3Nb13SfD9qs2s6haWEJO1DPIE3Hsqg8k+w5pviDS7rVYYobbV7zTIgxMzWax+ZIuPuhnVtv1Az6EVW0LwjoeiXDXVjYI1+4w97cO09y/wDvSyEuep4zigDMXxffankeGPDWo3qEZW7vx9gtz6f6weaR7rGR704aT4u1LB1PxFbaXEesGj2gZwPQzTbs/URqa6+igDkh8PfD8zB9Xgudak6k6tdSXa/hG5KD6BQK6SwsLPToBBp9pb2sI6RwRhFH4AYqzRQAUUUUAFFFFABXPat4L8O6rcfabvSLYXmCBdQAwTj6SxlXH4GuhooA5D/hG9d0zLeH/FFy0Y6WusRC8j+gkBWX8S7Y9PVv/CTa7pXHiTwxctEOt5oz/bY8epjwsw+io/1rsaKAOFhtPA/jG9kudOltRrCj95NZTNaX0ff59hWQeuG49qtf2P4s0ps6Pr8Gq2+f+PXWoQHA9FniAI/4Ejn3ra17w3o3iBEXWtMtL0x8xvLGC8Z9Vb7yn3BFY58I39hz4e8T6tZqOlvesL+H8fN/e49hIKAE/wCExudPYJ4l8O6ppwHW5tk+22313RZcD3dFrc0PX9I1+AzaJqdlfxj7xt5lfb7EA8H2NYouvG1iMXGm6Jq6DrJaXMlo5+kbq6/+RKzb+zs/ENyJNc+Hl+t4vC3ZNn5i+6TJPvX68GgDv6K4yDQvEWmrv0DXZ5IR/wAuGur9pAGeizqfMH1YyfSs62+KenWurz6R4ntm0zUrc4lMEgu4BwDncg3qvP3nRRx1oA9Eoqrpuo2WqWaXemXdveWsn3JreQSI30I4q1QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRXE61c3Pi3Wrjw9pU8kGkWh26vewsVdmIyLWJh0Ygguw5UEAEMcqAF5rGoeK7yfTPCk7WmmwuYr3WwobkHDRWwIwzgjBkOVTkYZgQvR+HtC07w/YCz0q3EUZYvI5JaSVz1d3PzOx7sSTVyxtLfT7KC0sYI7e1gQRxRRqFVFAwAAOgqegAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKzNd0DStfthb6zp9teRKdyeagJRv7yt1VvcEGtOigDyfU/hLLYXkmoeDNZubG8Y7ik8z5Y/wDXdfnb/tsJgP7tV4vHHizwtKlv4v0+KaI8CaZkti3P8NwP9Hc+gf7OT2U17BTJoo54nimjSSJwVZHGQwPUEHqKAOc0fxvouozxWss76bqMgytlqKfZ5n90DcSD/aQsPeumrgdW+HVvHbSJ4be3trZjvbSL2L7Rp0h9ojzCfQxlQDyVNUdC1GfSNQTTLiW70bVJTtg03VLk3NndEdra5I3ZP90nKj/lnQB6ZRWXpmtW17cvZyB7XUYxue1m4fGcbl7MvuM++DxWpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfjfV7qxtLXTtGKHXdUkNvZ7hlYuMvMw/uxrlvc7V6sK0vDmi2nh/R7fTbAP5MIJLu255XJyzue7MxLE9yTXO+CgNf1nUPF0jb4J82OlgjhLVGO6Qf9dXBbPdFj9K3tT1n7HrujaXHAZptQaZmO/b5MUaZaTGOfnaJMcf6zOeMEA1qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACqmq6bZavYS2WqWsN1aSjDxSqGU+/1HY9RVuigDzHxZod7pVtGbp73U9Ftm8y3vocyanpDYxvVsEzxgdQcvjOfM7X/B3jKb7Ra6X4luLWaW7AbTNXtB/omqRkEjaeiSgD5o8+65HA7+vMfHfhm00m0vbkWbXHhW6fzdUsIhhrR+v223xyjKfmcDryw+YEMAenUVyXgvW52nOhazcR3GpQQieC7QAJf2xwFnXHGeQGA6E+jKT1tABRRRQAUUUUAFFFFABRRRQAVyvxGupxoMelafI0Woa1OumwOn3ow4JlkHukSyOPdRXVVyEYGr/E6ZzhrfQbERp6faLg7m/FY40/CY0AdRYWkFhY29nZxLFbW8axRRqMBEUYAHsABXM6ePtvxQ1edjldN023tI/Z5XeST8wkH5V1tcp4O+fxH44mOSDq0canttWxtePwYvQB1dFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUhAYEEAg8EGlooA8th0J4L+88KWtx9ivdO/wCJp4avCN3kxMdrwkfxIjnYy5/1ckY4IBHa+D9fGv6a7TQ/ZNTtZDbX9mWybecAErnupBDK3dWB71mfEhGsbKx8TW4Jn0Gb7TKBnL2rDbcL74QlwP70a1D4wifQtRi8Z6WhkiijEWrQxc/aLTqJQB1eLJYdyhdepXAB21FMgljuIY5oHWSKRQ6OpyGUjIIPpT6ACiiigAooooAKKKKACuS+GoFxpGoaweX1fUbi83f3ow3lQn/v1FFWx4s1F9I8L6vqMShpLS0lnUFsDKoTyew4qTw3py6R4e0zTYwAlpbRQAAcfKoHf6UAaNYPhp4v7U8SwRqFeLUAXx3LW8LZ/I4/A1vVzukWz23jXxEf+WV1DaXI/wB/EkZ/SJKAOiooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBk8Uc8MkMyLJFIpR0YZDAjBBrlfhnJIvhl9HvCXudFuJNLkL8l0jx5TH1LQtEx/3q62uQtv+JZ8UbuL7sOt6etyvoZrdgjn6lJYfwjPpQAvgeB9CvdT8Muc2lmy3Omk9rSTOI/+2bq6j0XZXXVy3iaX7D4t8KXYz/pE8+nHHcPEZRn8YP8AOa6mgAooooAKKKKACiiigDmviWvmeAdeh7T2jwH6ONp/9Crpa5v4jHHgnVieAIgSfQBhk10lABXOazcNpvi/Q59rmDUfM0+U5O1XCmWIn0+5Iue5dR6V0dUNcsze6bJGiqZoys0OegkRg6fhuA/CgC/RUNjdRXtlb3Vud0M8ayoT3VhkfoamoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArkvHw+x3HhvWRwbDVIo5G/6ZXGbcg+26VGP+4K62sDx/p0mreCdcsbfIuZbOXyCP4ZQpKH8GCn8KAI/Gqqkei3jcC11S3bP/XQmH/2r/nrXR1ymsahFrHw+ttYiAMEsVrqS85G1Xjm/kK6sUAFFFFABRRRQAUUUUAYvjWD7T4P1uHIBeymCkngHYcH88VrwSLNDHIhyrqGBHoac6LIjJIoZGGGVhkEehrF8Fyo/hqyiVw72imzkPo8RMbZ/FTQBt0UUUAct4PuDZ6nrXh6UMDYzfabdm43285Z1x7I29OOyrXU1y3jON9PuNO8SW+7OmsyXaqPv2kmBJ/3wQkn0jYfxV1COroGRgynkEHINAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwfhO3MvwuvtIIGbNb7SwozwkUkkSfmiofxru0O5FYdxmuU+HwFzputXBGYrrV77aM9VSZouPr5ZP4/jW7oE5utC064PWW2jc/ioNAF+iiigAooooAKKKKACuX8Gf6JqXiPSY4DFbWl95sDDGGWZFlb8naT9PeuorHWZYPF8kDKQ13YrJGcjDeU5D/l5yfnQBsUUUUAI6h1ZWAKsMEHuK5Twt/xTl0PDF1IxgUFtKlc5MsOMtGT3aM/mpU8nNdZWT4l0f8AtiwCQzm1v4HE1pdKu4wSjocd1PKsvdSR3oA1qKyfDurHU7aWO5jW31K1byry2DZ8t8ZyD3Rhgqe4PY5A1qACiiigAooooAKKKKACiiigAoorI8ReI9M8PQxPqU5Es7bLe2iQyz3Df3Y41BZj9Bx3wKANeiuMjPjDxA2/MPhbTz91SiXV849TnMUX0xJ+FTr4HtpAPt+t+Jrx+7HV57fP4QNGP0/pQB1lFcofA9rH/wAeWteJbVux/tiefH4TM4P40g0DxLbECz8YzTIO2oafDMcemYxF+v60AdZRXKfYfHAH/Iw+G2PvoU4z/wCTlNe68a2Hzzabo2sRdxZzvayj/dWTcrfi60AdbRXJQeP9ES4S21o3WgXbNtWLV4Tbhj6LLzE//AXNdXFIk0SyQuskbDKspyCPY0AOoqI3MAultjNGLhlLiLcNxUcZx1x71LQAUUUUAFFFFABRRRQAU2R1jjZ5CFRQWYnsBTq5z4kXb2Pw/wDEU8H+vWwmWH3kZCqD/voigCD4Vo6/DvQJZQRLdWq3jg9Q0370598ua2PDOP8AhHNK242/ZIsY/wBwVFd/8SDwnKLRQ5sLMrCuPvFEwox7kAYq5pNobDSrOzLlzbwpFuPVtqgZ/SgC3RRRQAUUUUAFFFFABXK+NJDY6v4W1NeFj1EWcx/6Zzo0YH/f3yPyrqq534iWE+peC9Vhs033scQubVfWeJhLF/4+i0AdFRUFhdR31jb3cBzDPGsqH1VhkfoanoAKKKKAOX8V6Lem9g1/w5sGuWqeW8LttjvoM5MDnsc5KP8AwsfRmB0/DevWfiHTvtVkXRkYxT28y7ZbeUfejkX+Fh+vBGQQa1a5fxD4Zml1P+3fDlxHp+vqoSRnXMF6g6RzqOSB/C4+Ze2RlSAdRRWLoOurqMj2d7bPp+rwrumspWDHH9+NhxJHnow+hCnIG1QAUUVDe3UFjZ3F3dyrFbQRtLLI3REUZJPsADQBNRXGW2reLddgjudI0vTtJsJVDxS6rI8s7KeQxgjwFyOcGTPqAeKxPFd1Fo6Rp478eSxLNythpUH2R5x6KqGScj/ccfWgDqtX8Z6XYai2m2oudV1dcFrDTo/OlTPdzkJGPd2UVXGq+MbgZtvC2m2ynoL/AFco4+oihkGfYN+NcHZ/Eez0nT1svBHgyW3tBkhrxksoyf7xVQ8hPqWUE+tYOp+JvGesgre6+mnQN1g0m3EZx6GR9zH6jbWipyYHf+J9a1rSrXzvEvirw/4btieBaW7XFw/tGZDgn28pia4/T/GdtpdxPdeFvDl3e39wNsusa/c+XNMOo4Cs+30TEYHYCuVs9GsrW6a72PPet966uZGmlP8AwNiSB7DArRrWNBdQN2T4geNZjn7ToNsuc7Y7CV2HtuabB/75FJ/wnPjH/oJaZ/4Lz/8AHKw6Kv2UOwG2PHvjiP7t7oMoz0k02UH8xP8A0q5Z/FPxPajOpaBpmoL3NjdvA/4JIpB/77FcxRR7KIHpOnfGTwrMQmqyXmiTk4EeowGME/7LjKN+BNdlYeI9Gv1RrPVLOUPyu2UZP4V4FIiSIUkVXQ8FWGQaypPDWiSOXOk2SyHq6QqjH8QAah0F0A+o5Y4riFo5USWJxhlYBlYehHeuZf4feFjI0lvo8Nk7HcxsHe03H1PlFc14Xp0OpeH5PtHhXVrywlXn7PLM81tJ7NGxOB7rgivc/hz4vi8X6GZ3jW21O2c299abs+TKOeD3Ughge4IrGdNxA1dB8OaRoAl/siwhtpJsebKBuklx03ucs2PcmsnUtZuNA8WltYJXQNQSGG3uc5S2uQWBWT+6JNyBW6ZXBwSM9ZUF9aW+oWU9pfQR3FrOhjlikUMrqRggg9RUAT0Vw2mPdeCdTsdFuTNeeHLyUW+nXLvvksnIJW3lJOWQ4wj8kcK2eCe5oAKKKKACiiigArkviX++0fTdPxk6hq1lAR6oJ1lkH4pG4rra4q5u18SePtOtbBDLY+HpZLi7uf8AlmLpomiSFT/EyrK7N/d+XPJwAC54/uZRFoenWzbZ9S1a2iBHXZG3nyf+Q4XH411NcZA39ufE6WZPmsvD1qbfdnhrufazD6pEqf8Af412dABRRRQAUUUUAFFFFABSMoZSrDIIwRS0UAc54BYJoDWGTu0y5msNpOSqRyERD/v35Z+hFdHXJ6Y/9nfEbWLEjEWqWkWpR8dZI8QTfkotvzrrKACiiigAooooA5f4h6Tfaj4fln0IONesw02nskiIRLjGMurLggkcjnpkdaxfC9/4nvtHiuNJ1rStaMX7q4g1G0ezuI5h95JGQsEYHt5fockc16FXLeJfDMs18dc8OTpp/iJEC+Yw/c3iDpFcKPvL2DD5kzwcZBAGDXfE8QK3Pg55H9bPUoZE/OTyz/47VW/0zxF4tjNlrsNlo+gyY+0W0E5uLi7UHJjZ9qrGjdGA3EjIyua2fCPiFPEFhKZbaSx1O1fyL6wlIL20oGcZHDKQQysOGUg+wxfjD4lvPC/gx7nS/LF/c3EVnA0nRGkYLux3xnOOPrTSvoBmfE74gtpMo0Hw08c3iGdcvKRvjsY+hkcd2/ur3PXgGvLrLT4rWWWctJPezndPdztvmmb1Zzyfp0HYCm6Xp6WEUn7x57mZvMuLmU5kmc9WY/yHQDgVdrrhTUQCiiitACiiigAooooAKK8n8Q3clv4yuHNwupl7iOOO0juJobq36fcQfKy989+9a+kaVGnxHv7X7VqDW9rbxXEUbXcjDeTzkE8j2PFRz6geg0UUVYBXPtq2peG/E2oX2iZ+1vawXCKEL7tkhWXCAjcdhTjPOAK6CoJbSCW7guXTM8AZY3yRtDY3D3BwOvoKTVwPXtH0i88RaVa6k3jjVruxu4lli+wRQWsbKeQciMyD6b/XNW5fBEaI0mna94jtL3qs7apNcKD2zFKzRke23n9azPgOxPw1sh2W6uwPp9okr0GuFqzA871G5vtd0u+8J641vY+K0QXOn3CArBdvEwkiniBJPyuqF48kr6kEMes8J65F4h0K3v0jMMxzHc2zH57eZeJIm91YEe/UcEUvijSdJ1XS3XXYUa1t8ziUuY3gKjPmJIpDIwGfmUg14Dc+Ihf2sVx4V0XWrK5uYw0upX+svbtcD+FpEgYmRgpADPtYAYJ4oUXLYD6Vorxv4K6tq97rmoad4g1m/lvbWJZ4ojKkkFxC3y7vmTeGVhg4f+JfWvZKGrOzAKKKiuriG0tpbi6lSG3hQySSSMFVFAySSegA70gMTx7qlzpPhe6m04qNSnaOzsywyBPNIsUbEdwGcMfYGsIW2oaRdad4O8JT2tjFFYPdT393E1xISZApYLuUGRmLsWYkZOcHJFZHiLVdX1vQbnxKbb7N4d0u4t7+zgeM/aLuKGZHkuGHVFMaybExk53HsK6TW5UsvHvhjU1dTbahDPpbODlWdlWeI5+kMoH+/wC4oA3fDmi2ugaVHY2ZkcBmkkmmbdJPIx3PI7d2Ykkn8sDArToooAKKKKACiiigAooooAKKKKAOT8bxNa6p4Z1uJSTZX4tpsdfIuR5R/ASGFj7Ia6ys7xFpUWt6Je6bOSqXERQOvBRv4WHuDgj6VV8Fau+u+GLG+nQRXZUxXUQOfKnjYpKmfZ1YfhQBt0UUUAFFFFABRRRQBxviKP8Asjx34f1i3+VNSZtIvgOjgo8kDn3V0ZB/12P4cJ8ZLiTUfHum6ZKT9j0yyXUAmeHmleSNWPrtWJ8e7/SvQPGjC517whpqf6yXUTdvjqsUMLsW/wC+zEv/AAOuA8fWN3rHxbuY9LtpblrbSbeO4Ma5CEyysgJ7Egt1q6fxagc3RXQp4M19zgac4+siD+Zq9H8PtcdAWW2Qn+FpeR+QNdfPHuByFFdj/wAK81r1tP8Av4f8KUfDvWv71oP+2h/wpe0j3A42ir+r6Te6RcCHUIGiY8qeqsPYiqFXe4BRTIZY54UlgkSSJwGV0OQwPQgjqKfQAUUUUAFFFFABRRRQB3vwHvhHaa7oL8PZXZu4veG4Jf8ASRZh+Vep14h8JS3/AAsy5EZ+T+yGMvufOTZ/7Ur2+uKorSYHB/G69Nt8OdRtY32zam0emp7iVgr/AJR7z+FeVIoRQqgBQMADtXTfGbVBqHjXRtEibdFpsL6jcAHIErgxxAj12mY/lXNVvRVlcCbw/ff2P4+8M6hkhJLhtOmx3jnXAH/f1Yj+FfRVfMWoyJBdaNPM2y2h1Wzkmf8AuoJ05/PGfbNfTtZ1l7wGf4h1e10DQtQ1a/Zha2UDzybRliFGcAdyegHc14fe+N9T8Qa1pUHjGGz03wlc3SLcWsDmRgesQuJCAPLMgQMAAOQCSuc9f8etXjj0bS/D8b5udVvIy6Dr5ETCVyfQEoq/8CxXnlxBFc28kFxGskMilHRhkMD1Bop0+ZNsD6SkjSWJopEVo2UqykZBB7Yry1LC8bwtrHg+Ni+teHmjvNHaQnM0KN5lqc98FDC3+4c/eqX4La/eTRXvhrUpWuZNMjjktbp2y8lu5ZVV/VkKFd3cbSeck9F480+6iNn4k0WBptW0jcxgT713bNjzYPckAMv+2i9iayas7MDe0HVbfXNEsNUsiTbXkCTx56gMM4PoR0I7EVfrgvhzqNrHqWpaVZTrNpl0BrWkyL0e2nOZEH+5KWOOwkQV3tIAooooAKKKKACiiigAooooAK47Qv8AiS+PtZ0hsra6qg1ez9PMG2O5QfQ+U/1lauxrl/H9jcPp1trGmRPLqeizfbYY0+9OgBWWH33xlgP9rae1AHUUVW0u/tdU021v7CZZ7S5iWaGRejIwyD+RqzQAUUUUAFFFFAHk3jeaa9/4TzVo5pIotIsk0qBkco2WCTXO1hyCwaFMjoU9a9H0LQ9L0G0a30bT7Wxhdt7rbxhN7YxubHU4AGT6CvNNNT+2deXwzI2ITreoapqCnrIkE8bRRH2Jmgb/AHUx3r12gAooqK6uILO2lubqWOC3iQySSSMFVFAySSegA70AS0VxkHifWtd+fwroINg33NR1aVraOQf3o4grSMOmCwQHPBqZh47iTzFfwzdtjPkbJ7fJ9PMy/wCeygDe1vS7bWNPktbtAysPlbHKN2Ye4rwzWdLutIv3tL1Nsi8gjo47MD3Fey+F/EKa39st57SfT9UsXEd3ZzkFoyRlWVhw6MM7WHXBHBBAf4q0GDXtOaGRVW4QEwy90b/A9xWtOpyuz2A+ZbCS98PWsVhcWU93p9uojgubVd7LGBhVeP72QOMrnOO1a2m6tY6lvFlcpI8f34zlXT/eQ4I/EVq3trPY3cttdRmOeNtrKe1ZOq6TZakoa6tkkmjH7uTJR0P+y4+ZfwNdXoBforzbw3qnia48RXmlW8lvJBZr++lnc3KRt2jDgIxb6lsc11/2/WLb/j80hbhR1exuAx+u19uPoCaSlcDaorkb690m+1ASavf3dlEqBI7W482zUPk5YtkByRgDBwMH1rS0f7RaX4tVnkvtMmiMsFy7eY0ZBAMbP/EDnKk88MDnincDcqrqGoWmmwebfXEcCHgbzyx9AOpPsOakvUuJLWRLOaOC4YYSV03hD64749K73R2+GHgIpNNq2mXOs7cyXlxKLm8bjk4GTGvsoVRUTny9ALnwU8Pz29nfeI9Sge3vNVCJBDKMPDapnYGHZmZncjsCo6it/wAd+O9O8KRLAFN/rMyk2+nQuBI/bc5/gQHqx/DJ4ri/EPxebUoXtPAtq8sjZVtUu4ytvCPVF6yt6AYX1PauE07T0s3nmeWW5vrlvMubuc7pZ39WP8gMAdhWMabm7sB9ql5Nf6hqmrzRzapqEvmztHkIgAwsaZ52qBjnrknvirVFFdKVlYCC/tIr6yntLld0M6GNx7EYNdv4K+LVhZaALDxdM8OsaaginlcqFuFHCTAsR94DJ7Btw7VxsjrGjPIwVFGSzHAArE06eDW9Uu7gQ21xY22yK3nKBt0nJkKt6coOO4apnBS3Abd+K7nxR4kvteXTrm7urj9xbquFgtbZSdq+Y2AxJ+dim7lsdAK36KKcY8qsBY8F65B4Y+Isd9qu6HTL+0WwN11jhl8wlfM/uglgN3QdyK9q8XeIRoVnCltB9t1e9cw2FirbWuJMZ5P8KKOWboB74B8A1me1g0+QXsZmjm/ciBU3tOzcCNV/iJ6Yr174UeFr7TNJtNU8TTTXOuvapbIs7hzZW4+7CG7twC79WYDOQornrRs7gUbzwzceEvDVjrMMr3mqaRdT6ldCBdqyxTsWuooo/wCFcHeq92jXJySa9ItLmG8tYbm1kWW3mRZI5EOQ6kZBHsQalIyMHpXHfD1TpUus+GH4TSbgPZ/9ec2XiH0VhLGPaIViB2NFFFABRRRQAUUUUAFISFBJIAHJJrF8Y+KdI8HaFPq/iC7S1s4uBnlpGxwiD+Jjjp/SvLbLw94m+LrNqPjKa+8P+DpMG00G3fy5rqP+9csOQDx8n5Y6kA39a+MWlLq0mkeENN1HxbqsY/eJpShoYT6STH5R9RmqYl+MPiT/AFdv4e8G2jd5XN/dLn0x+7P44r0fw7oOleG9Lj07QbC3sLKPpFAm0E+pPUn1JyT3rToA+errwN4v8KXlnaaj8RNXj8O3krhrywtIrdLS5lkyFdMnZG7NwV4VjjABzXX/APCm/POdS+IHj675zs/tbYnTj5QvWvS9X0611fS7vTr+IS2l1E0MqH+JWGD/ADrF+Hd9c3vhS2j1GQy6jYvJp9056vJC5jLn/e2h/wDgVAHGj4CeCZQBqS6xqQ4BF3qczZHvtYU7/hnz4Yf9Cz/5P3X/AMcr1WigDyo/s/fDZSGt9BmtpB0ki1C5DfTmQ00fA7RYR/xLfEfjHTcYwbTV3XGOhGQa7jXPB+g63c/adQ09GvMAC5idoplx0xIhDD8DWPb3us+EJGtdXiv9b0Mf8e+owRme6gH9yeNRukx2kQEkD5hn5iAefa78HfEeiTSaz4M8a+ILnVM5mS+mjlmmTCj5ZGUDdhEGGwG2qCVABq94c0z4iappovdC+JsV4iO0UlrqmgxxS28i/ejk2ncGGeQfbHBBrv1+IvhEj59es4m7pMTG4+qsAR+IrB0u0HinxfreraFf6rpukzW9rG13aoIheXCGUMyiRDuUI0a7wMHAAJ2mgCiT8abD+HwPq0Y9PtEEp/8AZR/ia5nx/wCLfHsOk2f/AAlvw8T+xYb+3kvJLHVYpROocbY/LI3YMmw88HAU9a9KnXxZ4c/fR3H/AAlGmLzJDJGkN+i+qMgWOU/7JVCf7xPB3NPvtI8XeH2kgMV9pl0jRSxSJwezRyIwyCOQVIyKAE8J65/wkeiQ6l/Zeq6V5jMv2XVLfyJ1wSMsmTgHGRz0rQv721060kutQuYLW2jGXmnkCIo92PArk00bxF4aRV8N3keraYnTTdUkYSxr2WK5AJwOyyK3++BWr/wiXh+41MavdaDpzaoxEhnlgSSRWwMkMQeeMZFAGFouqwX+ta34yw9roEGnJbxXMyFPtKRtJI82Dz5Y3YU45+cjggnB8YeM9es9Eh1u4l/sLT7pxHY2MVsLjULosCV3bz5cRI527XwOpHIHXfFYK3w/1eN8bJUSJgf4g8iqR+IOPxrhPjWzyeOPDMUw/wBHjsbuaH3k3wqx+oVgP+BmqgruwHFalrXirV44572OyedCSBcODKyYGEZ4kRBggn7rfePJ4pmgrq3ie4utO062sra/RDutrq/MFxjGC6DyyGXJ4ZSR0zg8Vfqnqem22pRotyh3xNvilRikkTf3kYcqfpXXytK0WAvhr4H+MdAIaxvbBIMsxt59SaVWLdWYLbLk9P4u3WqWsXmqaRrp0rytL1i5iB+0/wBmXTn7N6By6BNx7Lvz68c1bkPiO4thZXnizVJLDG0pGfLkkX0aQH/0ELUthZW2n2qW9lCkMK9EQY+pPqfc9amEZLdgZy+INOZhBqHmWEr/AC+VfR+WGPoGPyN+BNLL4b0mRzLFaLbSNz5lo7QMfclCM/jWrNFHNG0cyLJGwwyuMg/UVz9/ojadZ3Fx4bkltLiONnS0Q5gkYDhfLPC56fLtq35gGpaVaWllJNqWo6pNZx4zC1w2GycBflwzEkgYJOScVa8MW0tvazF7KKwgkk3QWqKoMSbQPm28bidxPJxnGawZ9YuLtdGuNVt44tJ8xbtr6Fi8TYXKBlxmP5iCd3A24ya7WGSOaJJYXWSNwGV1OQR6g0KzYDqKKKoApk8scEMk0zhIo1LuzHAUAZJNMvLqCytpLi7mjhgjGWeRsAfjWDM0niWeGFIZ4tGQiWZ5o2jNyQcqgVgDs7kkc8DoTSbAdp2njXAup6zGZY5DvtbOUfu4o8/KzJ0LkYJJzjOBjHPQqqooVQFUcAAYApaKErAFI7qiM7kBVBJJ7ClqG+gNzZXEAO0yxsgJ7ZGKYHdfBTwolzaQeMtZjMmoXimTT4pM7bO3bhSq9A7Lyzdfmx04r1yvMfhP490O48G2NjqWo2enanpkCWt1b3UyxMhQBc/MRkccHpXoek6nZaxp8V9pdzFd2cufLmibcjgEglT3GQeRwe1cMr31At1yT7E+LMPln55dEfzgO4SdPLz/AN9y4/Go7/xTd6tez6X4Jihu7mJjHc6nMCbOzYdVyCDLIP7ing/eZa1PDPhuDQzc3D3Fxf6pebTd39y2ZJtucAAcIgycIoAGT3JJkDdooooAKKKKACob67gsLK4vLyVYba3jaWWRjgIijJJ9gATU1eb/ALRuoSab8E/FU8P33gS3P+7LKkbfo5oAwfh1osnxJ1OL4heMI2ltBI//AAj+lSD91awhsCdl/ikbGcn2I/h2+zVR0LTo9I0TT9Ngx5Nnbx26Y/uooUfyq9QAUUUUAFZ+laTBplzqc1sz/wDEwuvtcischX8tEO30B8sH6k1oUUAFFFFABRRRQAUUUUAFedfES21Pws114v8ACgtxJtX+1rSdW8maIYH2jC8iSNepHVARztUV6LTZESWNo5FV0YFWVhkEHqCKAPPPEFz44/4RXU9TbUdE0tLWzluk+wwtdvJtQsMSSYUA4H8DVo2fh3XPsVtc2XjPVvPeNXZb23tp4mJGeVWNGH/AWWq+gRLo9xceBdWZ2sJ4ZP7ImZv9bbYw1vn+/EDgdym087Wxp/Da+kn8LwWF7ganpB/s29Tp+8iAAfHo6bJB7OKAK7+HNc1e8s/+Ep1bT7jTrSdLkWlhZPALiVDuQyl5XO1WCsEGOQMkjisH49WRXQdL11AP+JTdjzz6W8o8tz+DGNj7Ia9PHvVLXNNg1nRr7Tbxd1teQPBIPVWBB/nTTs7gfPlFUtNt7vTjdaPqhJv9LmNpK5/5agAFJPo6FW/E+lXa7k7q4Gf4g1NdH0i4vmiMpjACxg43MSFAz25I5rO8NeJV1eeS0ubf7JfIu8R796umcblbAzjvwCK0td05NW0i6sZGKCZNoYdVPUH8CAa8uAu4bkwzH7NrNg4ZXA4zzhx6owyCPQkUAewUVm+HdWj1nS47pF2SZKTRE8xyDhl/w9QQe9aVMDB0gjTdXvdKc4hk3XtrnptY/vEH+65z9JB6VLLoEUUpm0i4m02VjllgwYnPctGflz7jB96n1lEj+zai9pFeixk82S2kQOtxCQVliIPB3IWx/tBT2rtdQ+FrxafFqfw81XzrKaNZ4tOvXMkMiMMjypfvICCMZ3D2rOUlF2YHBA+IYht8vSrvtv8AMkt/x27X/nQbbXbk/v7+0so/7trD5j/99vx/45V6W7msb5bDXrG50jUGO1IrpcLKf+mUg+WT8Dn1Aq5VKz2YGJJ4dimQC51HVJmyG3NcleQcg7VAXg89Kn0yHUrS7eC6uBeWOzdHPIAsytn7jAABhjkMMHjnPWtSinYAoorwq1uPEg8KaRNNeXH9nG6jmW48475CzhPKPOcDDnn+8KUpcoHutFeT6pfOviyeGO/vR4V+3Ri8mVztinwf3QfORGTt3Y4B44r1gYxx0ojK4GF4shjltI44baGXU7qRbS1Zog7K7fxDj+Fdzf8AAa9j0fTJfEdhHolhJJpvgzSR/ZrLAxSe/eH926bxykKspUkfM5DchfveY6FMieNLzWLpBJY+GdNkvmTrulYMQAP72EUAf7Zr3zwPpMmh+EdJ0+4O66igU3Df35m+aRvxdmP41z1ndgamn2Vrp1lDZ2FvFbWkChIoYlCoijsAOlWKKKxAKKKKACiiigAryr9qP/khPib/ALdf/SqKvVa5/wCIHh+38VeCda0S7ZEjvLZ0Ej9I3xlHP+6wU/hQB0FFeIfB/wCNGi6rpnhTwzqE1xL4rmQ2c8cce5UaIMN7vwp3BM/Lnlq9voAKKKKACiiigAooooAKKKKACiiigAooooAx/FWgW/iLSjaXDvBMjia2uouJLaZeUlQ+oPboRkHIJFeejWL3S9Yudau4BHrOmRpB4jsoASl1ac+Xewjknb8xx12+YhyVWvWq5bxxo1zcx22s6GiHxBpmXtwTtFzGceZbuf7rgcZ6MFbtQB0tvPFc28U9vIksMqh45EOVdSMggjqCKkrzb4fazZ6dcWmm2rEeHtW3z6MzjabeQZM1i4/hZCHZV7AMv8HPpNAHj/xt0g6fqmneKbdcQSbdO1HHQKW/cSn6OxQn0kHpXH19Ba5pVprmjXul6jH5lneQtBKvcqwwcHse4PY186WcV3ZyXemamd2o6bM1pO+MeYVAKyfR0KP/AMCrooy+yBZrmvGmhPqVsl5YKv8AadqCY+3mr/FGT79vQ4rpaK6APK/DWtJpepx3u4rp94RFdK3HlODhXI7EH5W/D0r1QcjivPPHWirYXM2qRIG066+W9jxwjHjzPoejfgfWrvgTWnjcaLqEhZ1Umzmc8yxj+Enuy/qOfWkB21d98ENVENte+GJmObEm5sgT1tnY5Uf7j5X2Vo64Gmx3V9pmpWWraR5Zv7JyyxyHCzxsMPEx7BhjnnDKpwcYqKkOZAfQeuaPp2u6bNp+sWcF5ZyjDRTIGH1HofQjkV4xr3w38Q+Hrpj4ZQ63ozHKW09wEurf/ZVm4kX03EEepr1LwV4x0vxbZu9i7Q3sGBdWM/yzW7Hsw7g9mGVPY10lcsZOL0A+Yb6/n0whda0fWtNYnA8+xkZSfZ0DKfzqsnibRXcI2p20Tnokz+Ux/BsGvqZlVhhgCPQisrVPDmj6rGyX+nW0obqdgBP4jmtVXfUDwKKWOaMPC6yIejKcg/jT69Jv/g14Sncy2Fvc6VcnrNYS+Ux/3uMN+INc3qXwo8SWQZtE8RW1/GDxFqVqFfHYb4yoz7la0VaLA5qqWq3xsoYxDC9ze3DiC1to/vTyt91R/MnsATWr/wAIz46hfZP4XjmPZrW/jIPud4XH5mu9+HXw+Hh+5k8ReKZ4Z9cMZCBT+4sIscqhOMn+85xnHGAKJVUloBl2Xg8+HvDeg6FdMlxq2v6xDPqkwHD+UDcOo/2AsAjA9D716/XEaLdHxh4qg1q2DDw9pSyJYzEY+2zuNrzL6xKuVVv4i7HoAT29cjdwCiiigAooooA4/wCIEJvNQ8Iae1zfQW15qzxz/Y7uW1eRFsrqQKXiZWxuRDjP8Iqb/hA9I/5/PEn/AIUeo/8Ax+jxl/yMfgT/ALDUn/puvK6qgDlf+ED0j/n88Sf+FHqP/wAfrA8dfCTSfE/ha/0tNQ1yKeZMwy3Gs3lyiSDlS0csrKw7HjOCcYODXpNFAH57fD/w5e+HPjpomgeIYrq0uo9QW2lFtO8L4fgMkiFWAIIOQRwa+3/+ED0j/n88Sf8AhR6j/wDH6zfiD8ObLxX4g8Na/Ey2utaLfQXCzgf66BJQzxNjkjG7HoSexNd5QByv/CB6R/z+eJP/AAo9R/8Aj9H/AAgekf8AP54k/wDCj1H/AOP11VZt7r2kWCM99qthbIuctNcIgGOucmgDH/4QPSP+fzxJ/wCFHqP/AMfo/wCED0j/AJ/PEn/hR6j/APH64rXPixPqLND4KtozbhiDqt7GTE49YYwQX7/MSF6Ebug6X4X+J9U11dRtNbiRp7Qo0d3DEUjnjYHgjJw6lSCAcEFSMZIFcrtcDQ/4QPSP+fzxJ/4Ueo//AB+j/hA9I/5/PEn/AIUeo/8Ax+uqoqQPOvFvhu10GwsL/TL/AMQJcpq2mx/vddvZkKSXsEbqyPKVYFWYEEHrXotcr8S/+Rcs/wDsNaT/AOnG3rqqACiiigAooooAKKKKAPMPHuhW+l3F1cys8Ph7Vpka9kiOG0y9BHlX0fp8wUP2yFY8b89b4J1m51TTprfVkSLW9OlNpfxpwpkABEiD+46lXX0DY6g1u3dtDeWk1tdRJNbzI0ckbjKupGCCO4IOK8m0Cafwn8QbTS76V2TYul+a5yZ7Zt72UjHuyFZ4CT1LIT94UAevV4R8TrF9K+JUs5/49tatVmjP/TaHCOPxQxEfRq93riPi/wCHJ/EPhF301A2r6bIL2yGcb3UHdHn0dCy/iPSqhLllcD54+JN/qlhpumHQ5fLvJ7+OEDAIcFHO057EgVyj+KddlHii4keWzWOyW5tLd0AaAFsAnI6kDPOetelWktlrVjZ3gijmiyJovNQExuMjOD91hyPUc1LPptjO8zz2VtI86COVniVjIo6K2RyPY11uLeqYHC+Etb1PUfFT6JrZ3G301xcIVGydt6bZBx/EjDj68Vm+JNCfQHAZpDpJcNb3Kth7R8/KCewB+634GvT1s7Zbv7UtvCLny/K84IN+zOdu7rjPOOlSTRRzwvFMiyRuCrKwyCD2IppNbgcr4X8U/aHj0/WWWK/+7HNjCXP09G9V/LPbra8517wbcWSudJi+3ac3Jsnb54v+uZPUex5HY9qraJ4o1GxJhST+0IIjte3uiUuIfbceT9GGfemB6JdWRkuob2zuJrHVLcHyL23bbJH7ejKe6nINdPZfETxtHaJDcJoEkyDBuGilJkx3KBgFJ9ia8/sfGekXBC3Ur6fL/dvF8sf998ofwNdDFLHMgeJ1dCMhlOQalwjLcDol+IXjZTuaXw3IP7g0+dP/AB77Qf5V0WkfF6x8lU8RaTqen3SjDvbwNdwsfVDGC+D1+ZQRXn1FS6MXsB6tF8WfBbkBtYaH/r4s54cfXegq/B8RvBc7bU8WaEH7I99GjH8CQa8apskaSoVkRXU9mGRUew8wPouyvLa/tkuLG4hubd/uywuHVvoRxXm/ivw9o+m+OxruvadBf6Nq7Q288lyN62dyoCRMyngxPhV5B2uFP8RI474VSnQ/iZbWNgqw2Gr2kxmt4xtQSxbWWQDoCQzAnvgV6z8Sp4o/BWqW8lul3LfRGxt7V+k80vyIh9BuYEnsAT2rGceV2A6ZVCqFUAKBgADAApaq6Vby2el2dtc3DXM8MKRyTsOZGCgFj7kjP41aqQCiiigAooooA5Xxl/yMfgT/ALDUn/puvK6quV8Zf8jH4E/7DUn/AKbryuqoAKKKKACuf8W+LdK8LwxHUZi11cEi3tIhulmI67R2A7scAdzXQV84+KHltviHrSa5vj1S5nY2zTcCW1H+qER6FQOqjkMWJGTk1CPM7ASeJNW1bxfcM2vS+VpvSPSoHPk49ZTx5rex+UdhnmuR17SNP3WOnWdhaW7XknlyPFCqFYFG5wCBxnAX/gVW/HM89p4V1G6tLuS1uIImlR025JAyAcg8Gs+wmljs/Ct/PcyXLTDyZppNuf3ybh0AH31Venp711WS0SAt6l4q07SPEEWj3atCWtTciXAEaqu75frhGNaHw+8ef6do3iKy+1QaY92bC8t5G4McjBA5UHGVfYc9hu9TWbrHhKy1nXmv9SxNAbVLf7OVIwVkLhtwPvjGKrf2J/YPgjWrUXXmMUublZdm3YSCw4yehxz7USTd09gPr2iobOUz2kEzLsaSNXK+mRnFTVxgcr8S/wDkXLP/ALDWk/8Apxt66quV+Jf/ACLln/2GtJ/9ONvXVUAFFFFABRRRQAVUuNTsLa8htLm9tYbqYZihklVXcZx8qk5P4VbrgPGOn6cvjXT7jX7C2vNG1a2GlSm4jV0hnDl4cgjgPvkXP97YOrCgDv685+L+hrfnRbpJPs8rz/2a1wOsXnEGB/cpcx2zD8fWr2jXE3g/XIfD+p3Es2jXrY0i7uHLtE+Mm0kc8k4GY2Y5YZU8qN1z4qr/AMW/1mX+O3jW6T2eJ1kX/wAeUUAaXg7WTr3h62vJkEV4N0F3CD/qbiNikqfg6tj1GD3rari0X/hHPiKQCF0zxIpbHZL+JOcf9dIlz9YT3au0oA8m8S/Ci5OtXeo+EtRtbFL1zLcWV3C0kXmHrIhVgVJ7jkHrxWU/w38YooKT+H5m7gyzRD89jfy/OvbqKtVJLqB4HdeDfG1r10Owux3+x6kG/wDRiR/5/Osa8i1zTgTqfhXXLZR1dYUnX/yE7H9K+laKpVpAfMNhq1lfyyQ28x8+MZeGVGikUepRgGA/CoNa0DTdZ2tfW4MyjCToSkifRhz+HSvoPxT4L0DxPCiavp8ckkZzFPGTHNEfVXXDD868s8Q/DnxLoJebQpx4g08c/Z7grFdoPQOMJJ+IU+5rWNZPRgeS3/hDU7QMdPuY9Qh/55XGI5MegcDa34gfWuYeGLTboCaK60a7Y4GGaDcfZlOx/wAzXq1rq9tLdmznWay1AdbO8jMUo+gP3h7rke9XJ4YriForiNJYmGGR1DA/UGtdwPOLfxBrlkm4X8F1EoyRdxAED/fTb+ZBrRsPH24A3umuU/562UgnX8uG/IGtK78D6RJuayWfT3PP+iyFV/74OV/SsOb4bB5C41KMt2d7Nd//AH0pWh+QHZ6PrenayjHT7lJWT78Zyrp9VPI/KtGuO0DwZc6MbiSDXrsTyhRlY1K4XOAQ+8nqehFa5HiC2BIk0y+Uf3le2bHuRvGfwFCb6gdp8Krcaj8UDMgDx6Rp0hkYfwyzugQH32xyHHuK9EhP/CRfEKaU5bTvDg8qP+7Jeyplm+scTBR7zOOorzv4Ea1NpHg+S/vvDetONTuXu2vLSFLlWDfMoKoxl4DAfc6Yrp/hZ418NHw7FHc63Y2+oXd1dXTJdSeRJNvuJGDhZMEggrgdhgdq46jvK4Hp9FIjK6qyMGVhkEHIIpagAooooAKKKKAOV8Zf8jH4E/7DUn/puvK6quV8Zf8AIx+BP+w1J/6bryuqoAKK8Y134a+L7C+n1Lwp4quZrh5HlKXNxJFIxJJwW+eJ+uAGiAAAGQKr+G/id4ohtpINa02zubuBmhk8xmtZEkU4IdVDqfXKnB6jANUot7Ae31l+I9B03xHpU2n6xapcW0g7j5o27OjdVYdQw5BrzGX4m+I3O2PS9Ig/22nllx/wHav865zW9f8AEviG3kt9Z1dY7KQFZLXTYTbJIp7M5ZpCPXDKD3GOKpUpPoBz9lBb6tocEeopb6jGPlLyRh0mKkr5gB45xkfWrOl+Hv7S0a/1GwtI4PDegQz3f7pRGl1cRqzCKPAxtVsszAY3ADk7sang3w4fF+ryaZAr2+gaeAl5PCdhL4BWCMjoQMFiOgIHU8eo/FNYNG+EXiG30+GK3hTTZLW3ijUKiFl8tFAHQZYCtKk7e6gPI4X8yGOTGNyhsemaq6raHVI7bR0zv1W4jseP7sjAOfwTe34VbjQRxqi/dUBRmum+EumHVfG9zqbrm00WLyYyehuZVyxHukRA/wC21a1JcsQPbAMAAdqKyfFHiHTfDGkvqWs3CwWyusYJPLOxwqgdzz+QJ6A1rVxAcr8S/wDkXLP/ALDWk/8Apxt66quV+Jf/ACLln/2GtJ/9ONvXVUAFFFFABRRRQAVS1rS7PWtKutN1OBZ7O5Qxyxt3B9+xHUEcgjNWppUgheWVgscalmY9AByTXAeCvFeryyab/wAJTFDHba+putKnjXbsDAyLayj/AJ6CPBDfxYYYyvIBLpw8wzeB/G4/tASxE2N3Nx9vgXB5YYxPHwWxg9HXHO2efwTf3MSafe+KNRvNCEiSPa3EUbTSKjBhG04AYpkc5BYjgt1zs+M/DqeJtFaz+0y2V3G6z2l7CMyWsy/dkX9QR3BI71kHX9e8Oqq+KdL+3WSjDaro6NIF/wBqW35kQd8oZAO+KANnxloz65oUtvayLDfxOlzZTMMiK4jYNGx9sjBHdSR3o8I6/H4h0n7R5TWt7C5t72zc/PbTr96M+vqD0ZSCOCKvaPq2n63YR3ukXtve2j/dlgkDr9MjofbqK5bxfD/wj2u2XiuyASOSWKx1eMcCaB3CJKf9qJ2Bz/cLj0wAdtRRVHWtWsNE0+S+1a7htLSPG6SVsDJ6AepJ4AHJPSgC9RXKL45sXUNHpPiRkIyG/sW5GR64KZ/Og+NrY8R6L4lduy/2ROufxZQB+JoA6uiuU/4S+5fi18JeJZz6eTBFz9ZJVFIureMLn57Xwrp1vH2XUdYMcn5RQyr/AOPUAaniXwzo3iayNrrmn295F1HmICyn1U9QfcV57dfB+W2lP/CP+JZ7a2PS31G2+2Kn+6wdH/76Zq683/jgAkeHfDZI7DXp+f8AyToOs+K48+b4TgcdR9n1VGP/AI+i/wCfSmpNbAcBd/DLxZGmbXVNDuGH8L28sWfx3tWTc+CvHlpE8h0vSLxUGSsN6yO30BQj8MivVT4p1WL/AI+vBXiBR/ehls5VP5T7v/HaP+E5sIj/AKbpfiK0/wBp9HuJFH1aNGA/E1aqyQHhel6rbajvjQtFdxcT2sw2Swt6Mp5H16HsTUXim4a18OalLH/rBbuI/dyMKPzIr17W9Q+Gfil44dau9G+1Z/dG5k+x3Kn/AGGOyQHnsa5HVPC3gm2u4obfX9a164WRJotDsrmG6aVlYMu4hN6pkAlncLxya09vpqB1tzHP4Z+HmjeGNIcLrmpILG0wOYiwzJMR/diTc31Cj+IV21rounW2h2ujraQvp1tClvHBKgdQirtAweOgrI8LaJerqNx4g8RmJtbuk8pIYm3R2MGQRCjEDcSQGd8Dc2OyqB1FYN31A5OT4eeGldpNOsH0iUnO/SbiSy59SImUH8Qc96VPDmu2Uqtpni69kiDZMGp2sVyuPQMgjf8ANjXV0UgPCPibceMl+N0a+CZpJp4PDqObB5tsL+ZPNF5pBOMoWjf1ITFcLoupX8XgzwpB4p1rV38JDXdQttav1nlEjBBiBZJFO9Yy2c84/SvrGigDgvCEvh1vDtofDuqaxcaT8/2eQzTSZXe3AZ8sVByASTwBjiiu9ooA5Xxl/wAjH4E/7DUn/puvK6quV8Zf8jH4E/7DUn/puvK6qgDjPHnjy38MyLY2do+pa1JH5iWyNsSNDkB5ZMHYpIIGAWODgHBx5P4U0rW/HGo30kNxGFkuXbUdVjT93FIR/q4FOd5UBV5yBwTkkivW/EHw58Pa/rUmp6nDevPKFWVI72aOOUKMLuVWAxjt0PfPNc38W9QOi6RpPhPw+iaZFfxyHzLceX5MEJj3JGFxhmMijI6DcetXF9I7gcB4mi8L20lxp3hqyudWubdjHdavqOp3It0ccEKsbqHYHqE2KPXPFVdPOzTUjhnhuZIk2bkPBIHHVifzJPvVefSAL2wubQ2oWyQrFaXVolxa9sExnHIAwCCMdsZNN8YanpbxQ6vqGj6fo3iHTkaSK6sV2WuoRAZliYYzHLsBZAd2SuAxyRWyvT3A9u+Cc2nzfDTRRprq7pFtvOzrddZg4PIbeWJB9fTFc58a9Xe71DTvDUBje3O2/vwCdyhGBhQ9sM4Lf9s/es74U61BomseKBcviwawj1ViuODHuSRvfKCL/vmuM/tC4uLe917Ukdr/AFBjdyxDkqWACQr/ALq7UH0z3qIw9/XoBYvrloEjSCF7m8ncRW1tH9+eQ9FUfqT0ABJwAa9a0fw5pnh7wPpnhrxABcy6tOY7hoty+ddOGmYhgQwA2HaeoCr6VP8AD7wNB4fRNS1LZda/LHtkn6pAD1jiB+6OmT1YjngACDx2y2virSr/AFgXqaFDZ3MS3dojP9kuZNq+a+0Er+73qr4IXc2cZFTUnzsDN8DeHNDuvCA1fxNNLqUhjurWS91a9kmAgDyREje22MOg5K4zuPOK6X4Y3Fzc+EoXnnnubYTTJY3FwCJZ7USEQu/AySgGG6sMMeSa43SR8JtPtrOFvEmlaotoqrbW95rAuxEFHy7IC5VSMdQma77RfFNnrd75Gm2upyQBSxu5LKSGD6BpAu7PqoI96zAqfEv/AJFyz/7DWk/+nG3rqq5X4l/8i5Z/9hrSf/Tjb11VABRRRQAUUUUAUNfsW1TQtSsI5DE91bSQCQHBQspXP4ZrmtHtrbxn8N7WzvIpLKZYxbyCMgSWd1A2wlD2ZJI8qfYHvXaVT07TrbTzdm0TYLmdrmQZ4LsBuI9M4z9SaAOK0nx/5VvBpGo2s+oeMIppLafTbAIsr+WT/pAEjoqROoDhmYD5woyeK6bw54lstde5ghS4tNQtCBc2N2nlzw5+6SuSCpwcMpKnsa265/xP4aTWJrW/sruTTdbswwtb6JdxVWxujdDxJGcDKn0BBBANAEer+C9I1C+fUIUn0zVX+9fadKbeZv8Afx8snXo4Ye1ZWs+EPEGqaTc6VP4t8+xuE8t2udNjabHrvjZFz77asT6t4z060le78O6XqPkoXL2GosjSgZ+7E8XDf7O8/Wul0bUbfV9IstSsXD2t3Ck8TDurKCP0NAFmeVIIJJpmCxxqXZj2AGSa4vwhpr+IpLPxf4gQSXEyedpdo3KWEDDKkDoZmUgs/bO0YA5tfE+eT/hFJNMtnK3etTR6VCQcEecdsjA+qx+Y/wDwGuqgijghjhhUJFGoRFHQADAFAD6KKKACiiigAooooAKKKKAI54IriJoriJJYm4ZHUMD9QajsrK1sYjHZW0FtGTkrDGEGfoKsUUAFFFFABRRRQAUUUUAFFFFAHK+Mv+Rj8Cf9hqT/ANN15XVVyvjL/kY/An/Yak/9N15XVUAFZfiHQNL8RWa22s2UV1Ejb0LZDRtjG5GGCpwSMgg81qUUAea3vwg0hogNK1TWtOkVcKRdfaFz6ssobI9gR7YrznxLpOqeEzs8VQQyWG4eXqkCk27YPHmA5MLdOuVz0YnivpCkZQylWAZTwQRwauNSUQPnLQrNtfsvG0mnsJoYfDtxZebEcgyzDcFBHcCMEjtuHqKo6fNHejw8wAKXd/YBVA4IaeMnj6ZNfS1ta29pAIbWCKGEZxHGgVRnrwK4rwx8LdB8PajaXcEl/dGzH+iRXUoaO342gqqqMkKSAWyR2qlU3v1A7uiiisgCiiigDlfiX/yLln/2GtJ/9ONvXVVyvxL/AORds/8AsNaT/wCnG3rqqACiiigAooooAKKKKACiszX9bttCtkub6K8a2LbXkt7Z5xF7uEBIX3xgd8Va02/tNUsYb3TbqG7tJl3RzQuHRx6gjigCyTgZPSuP+Fjxv4anNmd2l/2hdmwfHD25mZlK+qZJCnuoXHGKm+KE0ieCL+3gkMc1+0OnIwOCDcSpDwex/eE57da3bmay0PRpZpTHa6dYwF2wNqxRIvp2AA/SgDnJCdZ+JsaYDWnh+0Mh/wCvq4BVfxWJX/CcV2Fcv8ObK4g8PHUNRiMWp6xM2pXSMPmjaTGyM+6RiOP/AIBXUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcr4y/5GPwJ/2GpP8A03XldVXK+Mv+Rj8Cf9hqT/03XldVQAVx+p3et6r4tvdI0bUrbTIdPtIbiSR7Xz3meVpAowWACARH3JPUY57Cud8Q+GTqWqW+q6bqVzpWrwxGAXECq6yxE52SIwIYA5I6EEnB5IIBjy+Mrvwzf21j47htraK4LLBq1pu+zSFRnEinLQnGTyWXj73Yd1VHSdP/ALP06C2kubm9ePJa4un3yOxJJYnoOp4AAA4AAAFXqACiiigAooooAKKKKAOV+Jf/ACLln/2GtJ/9ONvXVVyvxL/5Fyz/AOw1pP8A6cbeuqoAKKKKACiiigAooooAK8p1rR9R8N/EL7Zo2opptrrsgEQ8gNam6CcxTxgjmQKWWVSG3ZVtwKiu917w9b6w8Uxu9RsbqIEJPY3Twtj0ZQdrj2ZSK5jXPC/iu9s00467YalYNPDKZr218q6gMcqyB1eLCOw2jA2Jz3oAvLpXiLXNV0uXxNFpVnYadKLpYLG5kuDczgEIzF402KuS20biWC/NxyvjJG1vxDo3hkvtsJ0k1DUABzJDC8YWIn+67uM+qow712Ncnp3+kfFDXJCfltdLsoEGejPJcO/5gR/l9KAOsooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5Xx1DqH2vwxf6bpdzqf9nam1xPBbSRJJ5bWlzFkea6KcNKnG7OKP8AhKNX/wChE8Sf9/8ATv8A5KrqqKAOV/4SjV/+hE8Sf9/9O/8Akqj/AISjV/8AoRPEn/f/AE7/AOSq6qigDlf+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkquqooA5X/hKNX/6ETxJ/3/07/wCSqP8AhKNX/wChE8Sf9/8ATv8A5KrqqKAOV/4SjV/+hE8Sf9/9O/8Akqj/AISjV/8AoRPEn/f/AE7/AOSq6qigDlf+Eo1f/oRPEn/f/Tv/AJKo/wCEo1f/AKETxJ/3/wBO/wDkquqooA4DxJfa34gtLKwi8Ha3af8AEzsLh57mex8uOOG7hlcnZcMx+WNuApJOK7+iigAooooAKKKKACiiigAooooAK5Tw6R/wnvi5cjdizbHfHlsM/ofyrq6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arch dermal mesenchyme forms mandible (MN), maxilla (MX), zygomatic temporal bone (Z), and squamous temporal bone (ST) through direct ossification. First-arch cartilage derivatives include the malleus (M); incus (I) alisphenoid (greater wing of sphenoid); and small fibrous core in mandible, which is called Meckel's cartilage (MC).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37504=[""].join("\n");
var outline_f36_40_37504=null;
var title_f36_40_37505="Patient information: Leptospirosis (The Basics)";
var content_f36_40_37505=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/39/33395\">",
"         Patient information: Avoiding infections in pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?21/59/22450\">",
"         Patient information: Rhabdomyolysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/42/27298\">",
"         Patient information: Staying healthy when you travel (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/2/16421\">",
"         Patient information: General travel advice (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Leptospirosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/leptospirosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H27200928\">",
"      <span class=\"h1\">",
"       What is leptospirosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Leptospirosis is a disease that can cause fever, muscle aches, and headaches. It is caused by a germ that infects animals. The germ lives in the urine of animals that carry it.",
"     </p>",
"     <p>",
"      The main way humans get leptospirosis is from water or soil with animal urine in it. The germ gets into the body through cuts or scrapes. It can also get in through the pink, moist tissues called &ldquo;mucous membranes&rdquo; that line your mouth, nose, eyes, and other body parts.",
"     </p>",
"     <p>",
"      Animals that can carry leptospirosis include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Rodents, such as rats and mice",
"       </li>",
"       <li>",
"        Farm animals, such as cows, pigs, horses, sheep, and goats",
"       </li>",
"       <li>",
"        Dogs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Leptospirosis is more common in certain parts of the United States. These include Hawaii, the South, and the Pacific coast states. The disease is also common in South America, Central America, South Asia, and islands in the Pacific Ocean.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200943\">",
"      <span class=\"h1\">",
"       What are the symptoms of leptospirosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Leptospirosis can be mild or severe. Some people have no symptoms or very mild symptoms.",
"     </p>",
"     <p>",
"      If symptoms do happen, they usually start suddenly. The main symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Shaking chills",
"       </li>",
"       <li>",
"        Muscle aches",
"       </li>",
"       <li>",
"        Headaches",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Whites of the eyes turning red",
"       </li>",
"       <li>",
"        Dry cough",
"       </li>",
"       <li>",
"        Nausea, vomiting, diarrhea, or belly pain",
"       </li>",
"       <li>",
"        Pain in joints or bones",
"       </li>",
"       <li>",
"        Sore throat",
"       </li>",
"       <li>",
"        Rash",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people get very sick with leptospirosis. They can have serious problems in the lungs, liver, muscles, and other body parts.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200958\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about your symptoms and do an exam. He or she can order tests to check for leptospirosis or a different condition that might be causing symptoms. Tests can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        Tests on samples of the fluid from your spinal cord (called &ldquo;cerebrospinal fluid&rdquo; or &ldquo;CSF&rdquo;)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200975\">",
"      <span class=\"h1\">",
"       How is leptospirosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people who get leptospirosis get better on their own. But if you feel sick enough to see the doctor or nurse, he or she can prescribe an antibiotic medicine. You can take this medicine by mouth. This helps most people get well faster.",
"     </p>",
"     <p>",
"      If you get very sick, you might need treatment in the hospital. Doctors can give antibiotics through an &ldquo;IV.&rdquo; This is a thin tube that goes into a vein. Doctors can also give treatments for serious symptoms such as breathing problems, if you have them. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27200990\">",
"      <span class=\"h1\">",
"       Can leptospirosis be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting leptospirosis by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Staying away from water or soil that might be infected, such as:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Puddles, ponds, or lakes where the water does not move much or has scum on it.",
"       </li>",
"       <li>",
"        Water that could have animal waste in it &ndash; For example, waste that drains from a farm or ranch",
"       </li>",
"       <li>",
"        Soil on a farm or ranch",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Keeping rats and mice out of your house or yard",
"       </li>",
"       <li>",
"        Not touching rats or mice",
"       </li>",
"       <li>",
"        Keeping food and drinks away from animals",
"       </li>",
"       <li>",
"        Getting your animals a vaccine (shot) against leptospirosis, if possible",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      There is no leptospirosis vaccine for humans in the United States.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H27201005\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/42/27298?source=see_link\">",
"       Patient information: Staying healthy when you travel (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/39/33395?source=see_link\">",
"       Patient information: Avoiding infections in pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/59/22450?source=see_link\">",
"       Patient information: Rhabdomyolysis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=see_link\">",
"       Patient information: General travel advice (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?36/40/37505?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83289 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-6C4A8C19E1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37505=[""].join("\n");
var outline_f36_40_37505=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200928\">",
"      What is leptospirosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200943\">",
"      What are the symptoms of leptospirosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200958\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200975\">",
"      How is leptospirosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27200990\">",
"      Can leptospirosis be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27201005\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/39/33395?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/59/22450?source=related_link\">",
"      Patient information: Rhabdomyolysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/42/27298?source=related_link\">",
"      Patient information: Staying healthy when you travel (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_40_37506="Stepwise asthma Rx 0 to 4 yrs";
var content_f36_40_37506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 636px\">",
"   <div class=\"ttl\">",
"    Stepwise approach for managing asthma in children 0-4 years of age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 616px; height: 543px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. If clear benefit is not observed within 4-6 weeks and patient/family medication technique and adherence are satisfactory, consider adjusting therapy or alternative diagnosis. Studies on children 0-4 years of age are limited. Step 2 preferred therapy is based on Evidence A. All other recommendations are based on expert opinion and extrapolation from studies in older children.",
"    <br/>",
"    <strong>",
"     Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.",
"    </strong>",
"    <div class=\"footnotes\">",
"     ICS: inhaled corticosteroid; LABA: inhaled long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist; SABA: inhaled short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37506=[""].join("\n");
var outline_f36_40_37506=null;
var title_f36_40_37507="Cardiac amyloidosis four chamber echocardiogram";
var content_f36_40_37507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/61904/4chamylo_conv.mp4?title=Cardiac+amyloidosis+four+chamber+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cardiac amyloidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 259px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four chamber view from a 2-D echocardiogram shows concentric hypertrophy of the right and left ventricular myocardium which has a \"sparkling\" appearance. The mitral and tricuspid valves are thickened and the right and left atria are dilated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37507=[""].join("\n");
var outline_f36_40_37507=null;
var title_f36_40_37508="Joint protection program for the upper limb";
var content_f36_40_37508=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Joint protection program for the upper limb",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37508/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37508/contributors\">",
"     Robert P Sheon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37508/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37508/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37508/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37508/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/40/37508/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Joint protection should be introduced to every patient with a chronic rheumatologic disorder in order to prevent recurrent sprains and strains which can add to inflammation and degeneration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37508/abstract/1\">",
"     1",
"    </a>",
"    ]. Conservative care includes preventive care, and joint protection is a fundamental way to provide preventive joint care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF JOINT PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general principles apply to all joints:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respect pain (which signals the patient to moderate or avoid activity)",
"     </li>",
"     <li>",
"      Balance work and rest",
"     </li>",
"     <li>",
"      Maintain strength and range of motion",
"     </li>",
"     <li>",
"      Reduce musculoskeletal effort",
"     </li>",
"     <li>",
"      Simplify work",
"     </li>",
"     <li>",
"      Avoid positions which induce deformity",
"     </li>",
"     <li>",
"      Use stronger, larger joints whenever possible",
"     </li>",
"     <li>",
"      Avoid staying in one position for too long",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These principles are derived from the simple, practical application of proper body mechanics, posture, and positioning of joints. Joint protection reduces local joint stress and preserves joint integrity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aggravating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggravating factors are those habits and activities that can initiate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perpetuate soft tissue rheumatic pain and disability. Whenever pain persists beyond the expected duration for a given problem such as bursitis or tendinitis, the clinician should consider a perpetuating aggravating factor as detailed below. Delving into the patient's routine at work, at home, and in sports is the starting point.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Questions you might ask in relation to localized pain",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Shoulder region",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have you engaged in a new sport or exercise?",
"     </li>",
"     <li>",
"      Have you pulled, reached, or carried a heavier object than usual?",
"     </li>",
"     <li>",
"      Have you had recent leg problems forcing you to use your arms more?",
"     </li>",
"     <li>",
"      Do you sleep with arms raised above your head?",
"     </li>",
"     <li>",
"      Do you do pushups?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Elbow region",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have you done any prolonged repetitive activity?",
"     </li>",
"     <li>",
"      Have you driven a long way with elbow on armrest of car door?",
"     </li>",
"     <li>",
"      Have you been pushing up from bed with your elbow?",
"     </li>",
"     <li>",
"      Are you under stress: are you clenching your grip unnecessarily firmly?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hand and wrist",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Have you done any prolonged repetitive activity?",
"     </li>",
"     <li>",
"      Has your job changed?",
"     </li>",
"     <li>",
"      Have you engaged in a new hobby, sport, or exercise?",
"     </li>",
"     <li>",
"      Are you under stress; are you clenching your grip unnecessarily firmly?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Personality assessment may also be important. The patient who is a compulsive worker with the attitude, \"I'm going to finish this job if it kills me,\" must learn to respect the pain signals, recognize potentially self-destructive behavior, and let reason prevail. Telling a patient not to do a task may not be as helpful as guiding the patient to perform the task in a manner that puts less stress on joints.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Systemic inflammatory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special considerations are required for persons with systemic inflammatory disorders involving the upper limb. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small finger joint inflammation may be more amenable to ice rather than heat.",
"     </li>",
"     <li>",
"      Squeezing actions should be avoided as they tend to further injure soft tissue as well as increase ulnar deviation. Many simple devices, such as jar openers, car door openers and key holders, are available to help limit these actions. Such patients generally benefit from evaluation by and instructions from a physical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occupational therapist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Energy conservation and joint protection can reduce pain and inflammation. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Seven hours of Joint Protection education in early RA (&le;12 months) provided improvement in self management but did not influence health status. Five years later functional status had declined little [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37508/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with longer disease duration (17-22 months) reported improvement in both inflammation and function. This included improvement in hand pain, general pain, morning stiffness, self-reported number of disease flare-ups, visits to the doctor for arthritis, and in activities of daily living [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37508/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GUIDELINES FOR UPPER LIMB PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following guidelines may be used to protect the upper limb from injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Shoulder",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevent cumulative movement disorders by frequently interrupting repetitive tasks such as washing windows, vacuuming, and working on an assembly line. Take a mini break and change position every 20 to 40 minutes. Keep the elbow close to the body. Change the angle of shoulder motion when possible.",
"     </li>",
"     <li>",
"      Sleep with the arms below the level of the chest.",
"     </li>",
"     <li>",
"      If using crutches, adjust them properly to about 5 cm below the axillae. Carry weight on the ribs and hands, not under the arms. A forearm cane may be preferred.",
"     </li>",
"     <li>",
"      Rise from a chair by pushing off with thigh muscles, not the hands.",
"     </li>",
"     <li>",
"      Take frequent breaks when working with the arms overhead.",
"     </li>",
"     <li>",
"      To grasp an object at your side or that is behind you, turn your body and face the object.",
"     </li>",
"     <li>",
"      Use the far arm and hand across the front of the body to reach a car seat belt.",
"     </li>",
"     <li>",
"      A swivel or wheeled chair may be useful when tasks done from a seated position are in various locations.",
"     </li>",
"     <li>",
"      Keep the hands below the 3 o'clock and 9 o'clock positions on the wheel when driving. If possible, use a steering wheel that tilts.",
"     </li>",
"     <li>",
"      Strengthen and maintain shoulder muscles with proper exercises if swimming.",
"     </li>",
"     <li>",
"      Learn the proper serving and stroke technique for playing tennis. Avoid tendinitis and impingement. Respect pain, avoid overuse, use frequent rest breaks. Relax your grip between strokes. Maintain shoulder strength through exercise; be aware of proper posture and positioning of joints. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1354?source=see_link\">",
"       \"Epicondylitis (tennis and golf elbow)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Avoid falling onto an outstretched arm if cycling. Learn to fall by pulling your arm in and rolling onto your shoulder.",
"     </li>",
"     <li>",
"      Perform conditioning exercises year-round to avoid golf shoulder injuries. Learn proper swing and impact.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Elbow and forearm",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoid pressure and impact to the elbow.",
"     </li>",
"     <li>",
"      Do not contact any firm surface with the elbow when sitting.",
"     </li>",
"     <li>",
"      Use the abdominal muscles to help roll over when getting out of bed.",
"     </li>",
"     <li>",
"      Do not push off with the elbow against a hard surface when changing body position.",
"     </li>",
"     <li>",
"      Use relaxation techniques focused on the hands and arms to protect the forearm muscles.",
"     </li>",
"     <li>",
"      Recognize and avoid repetitive hand clenching or excessively hard gripping. Wear stretch gloves with the seams to the outside for nocturnal hand clenching.",
"     </li>",
"     <li>",
"      Avoid forced gripping or twisting. Use kitchen aids such as jar openers, enlarged grips on utensils, or power tools.",
"     </li>",
"     <li>",
"      Take periodic breaks and alternate tasks during manual activities.",
"     </li>",
"     <li>",
"      Use a light and two handed grip when shaking hands repeatedly.",
"     </li>",
"     <li>",
"      Avoid prolonged use of tools requiring",
"      <span class=\"nowrap\">",
"       twist/force",
"      </span>",
"      motions.",
"     </li>",
"     <li>",
"      Hold tools with a relaxed grip. Use foam or plastic pipe insulation (sold at hardware stores) on tool handles.",
"     </li>",
"     <li>",
"      Take frequent short breaks.",
"     </li>",
"     <li>",
"      Do not lean directly on elbows; stabilize with the forearms.",
"     </li>",
"     <li>",
"      Change to a better work position or use elbow pads for protection.",
"     </li>",
"     <li>",
"      Use proper grip and play techniques with golf clubs, racquets, bats, or other pieces of sports equipment. Consult a pro for grip problems.",
"     </li>",
"     <li>",
"      Use elbow protective equipment when playing hockey, roller-blading, or skating.",
"     </li>",
"     <li>",
"      Use stretch, strengthening, and relaxation exercises to condition the tissues that surround the elbow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hand and wrist",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoid cumulative movement patterns.",
"     </li>",
"     <li>",
"      Interrupt repetitive tasks (eg, typing, peeling vegetables, knitting, playing cards) by short breaks.",
"     </li>",
"     <li>",
"      Rest the hands flat and open rather than tight fisted.",
"     </li>",
"     <li>",
"      Pad the handles on utensils, tools, and the steering wheel with pipe insulation.",
"     </li>",
"     <li>",
"      Use the stronger larger joints, especially the shoulders.",
"     </li>",
"     <li>",
"      Use the palms and forearms to carry heavy objects.",
"     </li>",
"     <li>",
"      Push, slide, or roll objects instead of lifting them.",
"     </li>",
"     <li>",
"      Use pencil grips and pad the stapler.",
"     </li>",
"     <li>",
"      Keep the hands off chairs when arising.",
"     </li>",
"     <li>",
"      Be aware of hand clenching and wear stretch gloves to bed when nocturnal hand clenching is recognized.",
"     </li>",
"     <li>",
"      Interrupt lengthy writing sessions by stopping for 1 to 2 minutes every 10 minutes.",
"     </li>",
"     <li>",
"      Use a relaxed grip on tools.",
"     </li>",
"     <li>",
"      Enlarge the handles of work tools; a 0.9 cm (2.25 in) diameter is optimum for most people.",
"     </li>",
"     <li>",
"      Texturize handle surfaces to provide an easy hold with less grip.",
"     </li>",
"     <li>",
"      Bend and straighten (wiggle) your fingers and wrist often.",
"     </li>",
"     <li>",
"      Wear stretch gloves while driving and at night if hand clenching is a habit.",
"     </li>",
"     <li>",
"      Grasp objects with the hand and all fingers. Use both hands as much as possible when lifting heavy objects.",
"     </li>",
"     <li>",
"      Use real tools, not the thumbs, to pinch and push in your daily job activities. Use pliers for hard to remove velcro fasteners.",
"     </li>",
"     <li>",
"      Power tools (eg, screwdriver, drill) are often preferable and easier to use than manual tools.",
"     </li>",
"     <li>",
"      Avoid uncomfortable hand positions.",
"     </li>",
"     <li>",
"      Keep the hand and wrist extended for work activities. Adapt tools with handles designed so that the wrist is straight.",
"     </li>",
"     <li>",
"      Use a wrist rest while working on a keyboard.",
"     </li>",
"     <li>",
"      Use an appropriate tool to hit or move objects.",
"     </li>",
"     <li>",
"      Fit the handles of vibrating tools with shock absorbers or rubber, or wear gloves with gel inserts. Avoid strong vibrations (greater than 12 meters per second squared) and vibrations lasting longer than one hour.",
"     </li>",
"     <li>",
"      Wear an appropriate splint for rest and activity if joints are painful (",
"      <a class=\"graphic graphic_picture graphicRef65557 \" href=\"mobipreview.htm?39/30/40430\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Consult an occupational therapist about work-induced problems, splinting, and modifying or adapting tools and equipment.",
"     </li>",
"     <li>",
"      Use proper grip size for racquet sports or golf. Golfers with arthritis should try using cushion grips and the baseball grip style (no interlocking fingers). Relax the grip until just before ball impact. Consult a pro for grip problems.",
"     </li>",
"     <li>",
"      Use a bowling ball with five finger holes. Bevel edges of the finger holes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A combination of joint protection education and hand exercises that can be performed at home may be of benefit to those with osteoarthritis of this hand. This was illustrated in a study that randomly assigned patients to this type of intervention or to education alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37508/abstract/4\">",
"     4",
"    </a>",
"    ]. A significantly larger proportion of those who received the combination intervention reported improve hand function and had a significantly greater mean increases in grip strength.",
"   </p>",
"   <p>",
"    Joint protection advice also appears to be valuable for patients who are considering hand surgery because of osteoarthritis of the thumb carpal-metacarpal (CMC) joint. As an example, in a prospective study, 33 patients scheduled for first CMC surgery were given joint protection advice and randomly assigned to receive one of two types of splints. After seven months of observation, the majority of patients had improved enough that surgery was no longer needed. In follow up at seven years, two of the remaining 19 patients wanted surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37508/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In my experience, not only do patients improve to the point that surgery is unnecessary, some considered too disabled to continue working, are able to return to work in the same job following referral to an occupational therapist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Systemic inflammatory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special considerations are required for persons with systemic inflammatory disorders involving the upper limb. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small finger joint inflammation may be more amenable to ice rather than heat.",
"     </li>",
"     <li>",
"      Squeezing actions should be avoided as they tend to further injure soft tissue as well as increase ulnar deviation. Many simple devices, such as jar openers, car door openers and key holders, are available to help limit these actions. Such patients generally benefit from evaluation by and instructions from a physical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      occupational therapist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     For patients",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.sjhc.london.on.ca/sjh/programs/arthritic/general/tips.htm\">",
"     www.sjhc.london.on.ca/sjh/programs/arthritic/general/tips.htm",
"    </a>",
"   </p>",
"   <p>",
"    St. Joseph's Hospital London, Ontario, Canada",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.arthritis.org/\">",
"     www.arthritis.org",
"    </a>",
"   </p>",
"   <p>",
"    Has many free booklets that provide useful information for patients",
"   </p>",
"   <p>",
"    www.webmd.com",
"   </p>",
"   <p>",
"    Provides general information including: Ask the Expert, Medical Library, Message Boards &amp; More",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.rheumatology.org/practice/clinical/patients/index.asp\">",
"     file://www.rheumatology.org/practice/clinical/patients/index.asp",
"    </a>",
"   </p>",
"   <p>",
"    Written by rheumatologists",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://orthopedics.about.com/\">",
"     file://orthopedics.about.com/",
"    </a>",
"   </p>",
"   <p>",
"    Written by orthopaedists",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.ccohs.ca/\">",
"     www.ccohs.ca",
"    </a>",
"   </p>",
"   <p>",
"    Canadian Centre for Occupational Health and Safety",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.bilbo.com/rsi.html\">",
"     www.bilbo.com/rsi.html",
"    </a>",
"   </p>",
"   <p>",
"    A commercial website with helpful information: hand and wrist problems arising from use of computers and other office devices",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.rsi.deas.harvard.edu/\">",
"     www.rsi.deas.harvard.edu",
"    </a>",
"   </p>",
"   <p>",
"    A website for repetitive strain injuries; maintained by Harvard students, very helpful (with illustrations)",
"   </p>",
"   <p>",
"    www.drleonards.com",
"   </p>",
"   <p>",
"    A catalog of energy saving devices",
"   </p>",
"   <p>",
"    www.sammonspreston.com",
"   </p>",
"   <p>",
"    A catalog of energy saving devices",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     For physicians",
"    </span>",
"   </p>",
"   <p>",
"    Crepeau, EB, Cohn, ES, Boyt Schell, BA. Willard and Spackman's Occupational Therapy, 9th edition. Lippincott, Williams &amp; Wilkins, 2003,",
"   </p>",
"   <p>",
"    Sanders, MJ. Ergonomics and the Management of Musculoskeletal Disorders; 2nd edition. Butterworth-Heinemann, 2003.",
"   </p>",
"   <p>",
"    Prentice, WE. Therapeutic Modalitites in Rehabilitation; 3rd edition.",
"    <span class=\"nowrap\">",
"     McGraw-Hill/Appleton",
"    </span>",
"    &amp; Lange (due September 1, 2005).",
"   </p>",
"   <p>",
"    Green, WB, (Ed). Essentials of Musculoskeletal Medicine, American Academy of Orthopaedic Surgeons 2001.",
"   </p>",
"   <p>",
"    Anderson BC. Office Orthopedics for Primary Care: Diagnosis and Treatment, 2nd ed, WB Saunders 1999.",
"   </p>",
"   <p>",
"    Claiborne, DK, Powell, NJ, Reynolds-Lynch, K. Ergonomics and Cumulative Trauma Disorders: A Handbook for Occupational Therapists. Singular Pub Group, 1999.",
"   </p>",
"   <p>",
"    Melvin, JL, Jensen, G. Rheumatologic Rehabilitation: Assessment &amp; Management. American Occupational Therapy Association, 1997.",
"   </p>",
"   <p>",
"    Nordin, M, Andersson, GBJ, Pope, MH (Eds), Musculoskeletal Disorders in the Workplace: Principles and Practice. Mosby-Year Book, 1997.",
"   </p>",
"   <p>",
"    Schwartz, SP. 250 Tips for Making Life With Arthritis Easier. Longstreet Press, 1997",
"   </p>",
"   <p>",
"    CTD News and The North American Ergonomic Resources Guide",
"   </p>",
"   <p>",
"    Center for Workplace Health",
"   </p>",
"   <p>",
"    Haverford, PA 19041",
"   </p>",
"   <p>",
"    800 554-4283",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://www.ctdnews.com/\">",
"     www.ctdnews.com",
"    </a>",
"   </p>",
"   <p>",
"    Human Factors and Ergonomics Society",
"   </p>",
"   <p>",
"    Box 1369",
"   </p>",
"   <p>",
"    Santa Monica, CA 90406",
"   </p>",
"   <p>",
"    (310) 394-1811",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://hfes.org/\">",
"     hfes.org",
"    </a>",
"   </p>",
"   <p>",
"    Applied Ergonomics",
"   </p>",
"   <p>",
"    Elsevier Science Ltd.",
"   </p>",
"   <p>",
"    Langford Lane",
"   </p>",
"   <p>",
"    Kidlington",
"   </p>",
"   <p>",
"    Oxford,OX5 1GB,UK",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://www.elsevier.com/locate/apergo\">",
"     www.elsevier.com/locate/apergo",
"    </a>",
"   </p>",
"   <p>",
"    American Industrial Hygiene Association",
"   </p>",
"   <p>",
"    2700 Prosperity Ave, Ste 250",
"   </p>",
"   <p>",
"    Fairfax, VA 22031",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://www.aiha.org/Pages/default.aspx\">",
"     www.aiha.org/Pages/default.aspx",
"    </a>",
"   </p>",
"   <p>",
"    Job Accommodation Network",
"   </p>",
"   <p>",
"    809 Allen Hall",
"   </p>",
"   <p>",
"    PO Box 6123",
"   </p>",
"   <p>",
"    West Virginia University",
"   </p>",
"   <p>",
"    Morgantown, WV 26506-6123",
"   </p>",
"   <p>",
"    1 (800) 526-7234",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://janweb.icdi.wvu.edu/\">",
"     janweb.icdi.wvu.edu",
"    </a>",
"   </p>",
"   <p>",
"    US Department of Health and Human Services",
"   </p>",
"   <p>",
"    4676 Columbia Pkwy",
"   </p>",
"   <p>",
"    Cincinnati, OH 45226",
"   </p>",
"   <p>",
"    Web site:",
"    <a class=\"external\" href=\"file://www.hhs.gov/\">",
"     www.hhs.gov",
"    </a>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sheon RP, Orr PM. Appendix B. A joint protection guide for rheumatic disorders. In: Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd, Sheon RP, Moskowitz RW, Goldberg VM (Eds), Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37508/abstract/2\">",
"      Hammond A, Young A, Kidao R. A randomised controlled trial of occupational therapy for people with early rheumatoid arthritis. Ann Rheum Dis 2004; 63:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37508/abstract/3\">",
"      Hammond A, Freeman K. One-year outcomes of a randomized controlled trial of an educational-behavioural joint protection programme for people with rheumatoid arthritis. Rheumatology (Oxford) 2001; 40:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37508/abstract/4\">",
"      Stamm TA, Machold KP, Smolen JS, et al. Joint protection and home hand exercises improve hand function in patients with hand osteoarthritis: a randomized controlled trial. Arthritis Rheum 2002; 47:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37508/abstract/5\">",
"      Berggren M, Joost-Davidsson A, Lindstrand J, et al. Reduction in the need for operation after conservative treatment of osteoarthritis of the first carpometacarpal joint: a seven year prospective study. Scand J Plast Reconstr Surg Hand Surg 2001; 35:415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7751 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5A1610FE52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37508=[""].join("\n");
var outline_f36_40_37508=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF JOINT PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aggravating factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Questions you might ask in relation to localized pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Shoulder region",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Elbow region",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hand and wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Systemic inflammatory disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GUIDELINES FOR UPPER LIMB PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Shoulder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Elbow and forearm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hand and wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Systemic inflammatory disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      For patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      For physicians",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7751\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7751|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/30/40430\" title=\"picture 1\">",
"      Thumb splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1354?source=related_link\">",
"      Epicondylitis (tennis and golf elbow)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_40_37509="Cavitary Cryptococcus";
var content_f36_40_37509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cryptococcosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 589px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest x-ray and CT show a cavitary lesion in the left lower lobe which was demonstrated to represent cryptococcosis by bronchoscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alan Fein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37509=[""].join("\n");
var outline_f36_40_37509=null;
var title_f36_40_37510="Direction of flow of cerebrospinal fluid";
var content_f36_40_37510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Direction of flow of cerebrospinal fluid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37510=[""].join("\n");
var outline_f36_40_37510=null;
var title_f36_40_37511="Embolic risk and the role of anticoagulation in atrial flutter";
var content_f36_40_37511=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Embolic risk and the role of anticoagulation in atrial flutter",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37511/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37511/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37511/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37511/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37511/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37511/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37511/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/40/37511/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained atrial flutter is an unusual arrhythmia. Most patients have periods of atrial flutter alternating with periods of atrial fibrillation (AF), which carries a similar risk of thromboembolism as AF. We evaluate and treat patients with atrial flutter with echocardiography and anticoagulation, as if they had pure AF. Anticoagulation is administered both prior to and after cardioversion and during long-term therapy of chronic atrial flutter-fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion applies to both types of atrial flutter: type I (typical, common, or isthmus-dependent) and type II (atypical or non-isthmus-dependent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THROMBI IN ATRIAL FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unfortunate limitation in the literature on atrial flutter is the definition of the arrhythmia. In many studies, a patient is defined as having atrial flutter if this rhythm is noted during the intervention or period of observation (eg, at the time of echocardiographic study or cardioversion). However, many patients have alternating periods of AF and atrial flutter, making it difficult to evaluate the risk of thrombus formation in pure atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both mitral valve M-mode and transmitral Doppler studies demonstrate some organized atrial mechanical function with sustained atrial flutter. This is presumably responsible for the much lower risk of thromboembolism following cardioversion for atrial flutter compared to AF. One study, for example, performed transesophageal echocardiography (TEE) immediately before and after cardioversion in 19 patients with atrial flutter and 44 patients with AF with the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to cardioversion, patients with atrial flutter had greater left atrial appendage flow velocities and shear rates compared to those with AF.",
"     </li>",
"     <li>",
"      After cardioversion, left atrial appendage flow velocities and shear rates decreased in both groups of patients, but the impaired left atrial appendage function was less pronounced in patients with atrial flutter. New or increased spontaneous echo contrast, a marker of blood stasis, occurred significantly less often in patients with atrial flutter (21 versus 50 percent for AF).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TEE evidence of atrial thrombi has been documented in a number of reports of patients with atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. The frequency with which this occurs may vary with the duration of the arrhythmia and other factors as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two series evaluated patients with atrial flutter for a mean duration of 33 to 36 days who did not have a history of AF, rheumatic heart disease, or a prosthetic heart valve [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. A left atrial thrombus was found in 1 to 1.6 percent, a right atrial thrombus in 1 percent, and spontaneous left atrial echo contrast in 11 to 13 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. In one of these reports, there was a close correlation between a history of previous embolism and periods of AF during atrial flutter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atrial thrombi and spontaneous echo contrast may be more common in patients with atrial flutter of longer duration. In a TEE study of 30 patients with chronic atrial flutter (duration 6.4 months), two patients (7 percent) had thrombus in the left atrial appendage, and 25 percent had spontaneous echo contrast prior to cardioversion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/5\">",
"       5",
"      </a>",
"      ]. As described below, left atrial contractile function transiently declines after cardioversion in many patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the predictive value of the duration of the arrhythmia has not been uniform. Left atrial thrombus was present in only five of 47 consecutive patients (11 percent) with atrial flutter for a mean duration of 28 days who did not have a history of AF or mitral stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A higher incidence of intraatrial thrombi (21 percent) was described in another report of 24 patients with atrial flutter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/7\">",
"       7",
"      </a>",
"      ]. However, the majority of these patients were referred for TEE because of a recent neurologic event, indicating an important selection bias. Depressed left ventricular systolic function was more common among those with thrombi, as was spontaneous left atrial contrast.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EMBOLIC RISK RELATED TO CARDIOVERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2012 American College of Chest Physicians (ACCP) guideline on antithrombotic therapy for atrial fibrillation recommend managing anticoagulation in patients with atrial flutter in a manner similar to that to those in AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/9\">",
"     9",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Recommendations for anticoagulation'",
"    </a>",
"    below), though recognizing that no report has been sufficiently large to accurately define both the risk of embolization and the possible protective effect of anticoagulation. As mentioned, an often confounding factor is that many patients with atrial flutter also have episodes of AF and thus there is heterogeneity of patient populations. Studies that included patients with a prior history of thromboembolism were more likely to report high event rates, while studies in which at least some patients were anticoagulated or underwent echocardiography before cardioversion were more likely to report low event rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety of performing cardioversion without anticoagulation in patients with atrial flutter was initially suggested by the absence of clinical thromboembolic events in a total of 314 patients from three series who underwent elective cardioversion for atrial flutter without anticoagulation prior to or after cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, both left atrial thrombi and spontaneous echo contrast (a marker of stasis) have been described in patients with atrial flutter, even in the apparent absence of AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/3-8\">",
"     3-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Thrombi in atrial flutter'",
"    </a>",
"    above.) In addition, a number of observational studies have documented the occurrence of embolic events after cardioversion for atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/3,13-16\">",
"     3,13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two large series of patients with atrial flutter in the apparent absence of AF, the incidence of postcardioversion embolic events was 0.6 and 1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Higher values have been described in patients who also have a history of AF or underlying heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Although the data were not conclusive, a number of these reports found no embolic events in patients who were adequately anticoagulated prior to cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Atrial stunning",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transient reduction in atrial mechanical activity, called atrial \"stunning.\" is common after successful cardioversion of atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/2,5,6,18,19\">",
"     2,5,6,18,19",
"    </a>",
"    ]. In one report, left atrial appendage velocity fell by 26 percent within 15 minutes of cardioversion and almost one-half had new or worsened spontaneous echo contrast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/5\">",
"     5",
"    </a>",
"    ]. These changes predispose to de novo thrombus formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/13\">",
"     13",
"    </a>",
"    ]. Similar observations have been made in patients with AF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=see_link&amp;anchor=H10#H10\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\", section on 'Atrial stunning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial stunning appears to be less pronounced in atrial flutter than in AF, which could explain the lower embolic risk after cardioversion in atrial flutter. In a report that compared 19 patients with atrial flutter to 44 with AF, the left atrial appendage flow velocity was significantly higher in the patients with atrial flutter at baseline (42 versus 28",
"    <span class=\"nowrap\">",
"     cm/sec",
"    </span>",
"    in atrial fibrillation) and after cardioversion (27 versus 15",
"    <span class=\"nowrap\">",
"     cm/sec)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, new or increased spontaneous echo contrast was significantly less likely in those with atrial flutter (21 versus 50 percent).",
"   </p>",
"   <p>",
"    Atrial stunning also occurs after radiofrequency ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The likelihood of developing atrial stunning and its duration were assessed in a review of 15 patients with chronic atrial flutter (mean duration 17 months) and seven with paroxysmal atrial flutter who underwent radiofrequency catheter ablation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/19\">",
"     19",
"    </a>",
"    ]. Significant left atrial stunning and spontaneous echo contrast on TEE were observed after ablation in 80 percent of those with chronic flutter but in none with paroxysmal atrial flutter, suggesting that, like AF, left atrial stunning in atrial flutter is related to the duration of the arrhythmia and not the mode of reversion. These changes resolved after three weeks of sinus rhythm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24888?source=see_link&amp;anchor=H3#H3\">",
"     \"Maintenance of sinus rhythm after cardioversion in atrial flutter\", section on 'RF ablation in type I atrial flutter'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EMBOLIC RISK IN CHRONIC ATRIAL FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be an increased risk for clinical thromboembolism in patients with chronic atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/1,10,16,17\">",
"     1,10,16,17",
"    </a>",
"    ]. In a systematic review based upon limited data, the long-term embolic risk in patients with sustained atrial flutter was estimated to be approximately 3 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one study evaluated 100 patients referred to an electrophysiology laboratory for cardioversion of atrial flutter that was present for least six months: 13 patients had a thromboembolic event that was attributable to atrial flutter in six [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/17\">",
"     17",
"    </a>",
"    ]. The embolism occurred during atrial flutter or after cardioversion; none of these patients was receiving adequate anticoagulation. There were no embolic events in patients on adequate anticoagulation therapy.",
"   </p>",
"   <p>",
"    Similar results were noted in a series of 191 patients referred for cardioversion or ablation of atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/16\">",
"     16",
"    </a>",
"    ]. During a follow-up of 26 months, an embolic event occurred in nine patients (5 percent), only one of whom was receiving therapeutic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation. In three of the patients, the embolic event was related to cardioversion. Using multivariate analysis, only a history of hypertension was an independent predictor of embolic risk.",
"   </p>",
"   <p>",
"    One problem with interpreting these data, as mentioned previously, is that many patients with chronic atrial flutter (34 percent in the preceding report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/16\">",
"     16",
"    </a>",
"    ]) also have a history of AF. In a review of the Medicare database, the risk of stroke was significantly increased in patients with atrial flutter (relative risk 1.41 compared to a control group). In these patients, the relative risk was 1.56 in patients who subsequently had an episode of AF (similar to the risk with AF alone), while those with isolated atrial flutter had a stroke risk not significantly different from the control population (relative risk 1.11) (",
"    <a class=\"graphic graphic_figure graphicRef67382 \" href=\"mobipreview.htm?22/12/22734\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for embolization in addition to AF include valvular heart disease (eg, rheumatic heart disease, prosthetic valves), depressed left ventricular systolic function, a history of thromboembolism, and atypical atrial flutter. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lone atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial flutter without an identifiable predisposing factor is called lone atrial flutter. It is relatively uncommon, occurring in only 3 of 181 adults with atrial flutter in a population-based study (1.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/21\">",
"     21",
"    </a>",
"    ] and in 8 percent of children and young adults with atrial flutter in a multicenter series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lone AF has been extensively studied and is associated with a relatively low embolic risk (approximately 0.3 percent per year in younger patients and 0.9 percent per year in patients over age 60). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link&amp;anchor=H439358969#H439358969\">",
"     \"Overview of atrial fibrillation\", section on 'Lone AF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the embolic risk associated with lone atrial flutter may be higher. This issue was evaluated in a review of 59 mostly elderly patients with lone atrial flutter (mean age at diagnosis 70 years) from the Mayo Clinic; 75 percent developed recurrent episodes or chronic atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/23\">",
"     23",
"    </a>",
"    ]. At presentation, these patients did not have coronary heart disease, hyperthyroidism, heart failure, valvular heart disease, congenital heart disease, obstructive lung disease, uncontrolled hypertension, or known antecedent AF. At the time of diagnosis, 25 were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and six with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ; at last follow-up, 28 were treated with aspirin and 13 with warfarin.",
"   </p>",
"   <p>",
"    The following observations were noted at an average follow-up of 10 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AF developed in 33 patients (56 percent), which was paroxysmal in 25 and chronic in eight.",
"     </li>",
"     <li>",
"      One or more ischemic cerebrovascular events occurred in 19 patients (32 percent) at a mean age of 80, including six who were in AF at the time of the event. Compared to age- and sex-adjusted expected rates of thromboembolism, the thromboembolic risk was significantly increased in the patients with lone atrial flutter (hazard ratio 5.2 in patients with controlled hypertension and 2.5 in patients without a history of hypertension).",
"     </li>",
"     <li>",
"      When compared to patients with lone AF, the patients with lone atrial flutter had, after adjustment for age and sex, a significantly higher rate of thromboembolism (hazard ratio 2.6). The risk was lower and no longer significant when only patients without a history of hypertension were included (hazard ratio 1.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors concluded that the thromboembolic risk was sufficiently large that anticoagulation was warranted in patients with lone atrial flutter over the age of 65.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As illustrated by the above observations, there are conflicting data in the literature concerning the embolic risk in patients with atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/10,24\">",
"     10,24",
"    </a>",
"    ]. At least part of the variability is related to heterogeneity of patient populations. Studies that included patients with a prior history of thromboembolism were more likely to report high event rates, while studies in which at least some patients were anticoagulated or underwent echocardiography before cardioversion were more likely to report low event rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We use the following approach to anticoagulation in such patients. Patients presenting with an initial episode of atrial flutter should have a transthoracic echocardiogram to evaluate for possible rheumatic mitral valve disease and to assess left ventricular systolic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Relation to cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with AF, there is an increased risk of thromboembolism following cardioversion of atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/3,13-16\">",
"     3,13-16",
"    </a>",
"    ]. The overall incidence is 0.6 to 1.0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/14,15\">",
"     14,15",
"    </a>",
"    ] with a higher risk in patients with a history of AF or underlying heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/13,16\">",
"     13,16",
"    </a>",
"    ]. Although the data are not conclusive, a number of reports found no embolic events in patients who were adequately anticoagulated prior to cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Embolic risk related to cardioversion'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Guidelines from the 2012 ACCP guideline on antithrombotic therapy in AF and a 2006 Task Force of the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    recommended that consideration be given to managing anticoagulation during cardioversion of atrial flutter in a manner similar to that for AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/9,25\">",
"     9,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We recommend the following approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients presenting with an initial episode of atrial flutter should have a transthoracic echocardiogram to evaluate for possible rheumatic mitral valve disease and to assess left ventricular systolic function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     High thromboembolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atrial flutter who have valvular heart disease, depressed left ventricular systolic function, hypertension, a history of thromboembolism, atypical atrial flutter, or a prior history of AF are at increased risk for atrial thrombus formation and are best treated conservatively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      &mdash; Traditionally, these patients are treated with three to four weeks of therapeutic warfarin prior to cardioversion. The goal INR is 2.0 to 3.0. It has been suggested that it may be prudent to aim for a minimum INR of 2.5 immediately before cardioversion or documentation that the INR has consistently been &ge;2.0 in the three to four weeks before cardioversion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/26\">",
"       26",
"      </a>",
"      ]. Warfarin therapy is continued for at least a month after cardioversion at a goal INR of 2.0 to 3.0. The oral thrombin inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      and the oral factor Xa inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      are alternatives to warfarin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H524842274#H524842274\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Direct thrombin and factor Xa inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TEE &mdash; Another option, which has been evaluated in patients with AF, is TEE-guided early cardioversion. After initiation of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or short-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ), if no left atrial thrombus is seen, cardioversion can be performed with continuation of warfarin (or dabigatran or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      ) for a month after cardioversion. The safety of the expedited TEE approach has not been formally studied in atrial flutter, but it appeared to be effective in the subgroup of 58 patients with atrial flutter in the ACUTE trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, thromboembolism has been reported after a negative TEE in some patients who were not anticoagulated at the time of and for one month after cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. These adverse events may be related to the limited sensitivity of TEE in some cases, but new thrombus formation has been documented during the period between TEE and cardioversion or after cardioversion.",
"   </p>",
"   <p>",
"    Due to this low likelihood of thromboembolism, we strongly recommend therapeutic anticoagulation at the time of and following cardioversion, even when the TEE does not show thrombus. For AF, an INR of &gt; = 2.5 may be preferred to further minimize embolic events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Low thromboembolic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with atrial flutter who have none of the above high-risk features are at low risk for thromboembolism related to cardioversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/4,11,12,14\">",
"     4,11,12,14",
"    </a>",
"    ], we generally perform cardioversion without long-term anticoagulation or screening TEE, if the arrhythmia has been present for a short period of time (&lt;48 hours).",
"   </p>",
"   <p>",
"    As in patients with AF, cardioversion can be safely performed with short-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    prior to cardioversion if the arrhythmia duration is less than 48 hours",
"    <strong>",
"     and",
"    </strong>",
"    the patient has no high-risk features. The optimal approach after cardioversion in this group is unproven. Our current practice is to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for a first episode of atrial flutter that converts spontaneously; aspirin is given for at least four weeks but, since most patients are over age 45, we usually recommend chronic aspirin therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ) is given for at least four weeks to all other patients (goal INR 2.0 to 3.0). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link&amp;anchor=H16#H16\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\", section on 'AF of less than 48 hours duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chronic or recurrent atrial flutter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic or recurrent atrial flutter who also have periods of AF (atrial flutter-fibrillation) should be treated in the same manner as those with pure AF&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/25\">",
"     25",
"    </a>",
"    ]. This recommendation also applies to patients with atrial flutter who have a prior history of atrial fibrillation.",
"   </p>",
"   <p>",
"    The optimal management of atrial flutter alone is uncertain since, as noted above, the increase in embolic risk may be limited to patients who also have AF (",
"    <a class=\"graphic graphic_figure graphicRef67382 \" href=\"mobipreview.htm?22/12/22734\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the 2012 American College of Chest Physician guideline on antithrombotic therapy for atrial fibrillation recommended that decisions regarding anticoagulation of atrial flutter follow the same recommendations as for AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with AF, the choice between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is based upon the estimated stroke risk. The CHADS2 score is currently the best validated and most clinically useful model (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H23#H23\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Specific patient groups'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal management is also unclear in patients with lone atrial flutter. Patients with lone AF are at low embolic risk (approximately 0.3 percent per year in younger patients and 0.9 percent per year over the age of 60) and are generally treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    In contrast, the thromboembolic risk appears to be higher in patients with atrial flutter, particularly those with a history of hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/23\">",
"     23",
"    </a>",
"    ]. It has been recommended that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy should be considered in such patients who are over age 65 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37511/abstract/23\">",
"     23",
"    </a>",
"    ] using the CHADS2 criteria and giving anticoagulation to those with a CHADS2 score of greater than 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190086348\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are conflicting data in the literature concerning the embolic risk in patients with atrial flutter. At least part of the variability is related to heterogeneity of patient populations. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Embolic risk in chronic atrial flutter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients presenting with an initial episode of atrial flutter should have a transthoracic echocardiogram to evaluate for possible rheumatic mitral valve disease and to assess left ventricular systolic function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Embolic risk related to cardioversion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We generally perform cardioversion without prolonged anticoagulation or screening transesophageal echocardiogram in patients at low embolic risk if the arrhythmia has clearly been present for a short period of time (&lt;48 hours). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recommendations for anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anticoagulant approach to patients with chronic or recurrent atrial flutter who also have periods of atrial fibrillation (atrial flutter-fibrillation) should be similar to those with atrial fibrillation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recommendations for anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with atrial flutter who have rheumatic heart disease, depressed left ventricular systolic function, hypertension, a history of thromboembolism, atypical atrial flutter, or a prior history of atrial fibrillation are at increased risk for atrial thrombus formation and should be anticoagulated prior to cardioversion. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Recommendations for anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/1\">",
"      Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol 2001; 87:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/2\">",
"      Grimm RA, Stewart WJ, Arheart K, et al. Left atrial appendage \"stunning\" after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events. J Am Coll Cardiol 1997; 29:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/3\">",
"      Corrado G, Sgalambro A, Mantero A, et al. Thromboembolic risk in atrial flutter. The FLASIEC (FLutter Atriale Societ&agrave; Italiana di Ecografia Cardiovascolare) multicentre study. Eur Heart J 2001; 22:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/4\">",
"      Schmidt H, von der Recke G, Illien S, et al. Prevalence of left atrial chamber and appendage thrombi in patients with atrial flutter and its clinical significance. J Am Coll Cardiol 2001; 38:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/5\">",
"      Weiss R, Marcovitz P, Knight BP, et al. Acute changes in spontaneous echo contrast and atrial function after cardioversion of persistent atrial flutter. Am J Cardiol 1998; 82:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/6\">",
"      Irani WN, Grayburn PA, Afridi I. Prevalence of thrombus, spontaneous echo contrast, and atrial stunning in patients undergoing cardioversion of atrial flutter. A prospective study using transesophageal echocardiography. Circulation 1997; 95:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/7\">",
"      Bikkina M, Alpert MA, Mulekar M, et al. Prevalence of intraatrial thrombus in patients with atrial flutter. Am J Cardiol 1995; 76:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/8\">",
"      Orsinelli DA, Pearson AC. Usefulness of transesophageal echocardiography to screen for left atrial thrombus before elective cardioversion for atrial fibrillation. Am J Cardiol 1993; 72:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/9\">",
"      You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/10\">",
"      Ghali WA, Wasil BI, Brant R, et al. Atrial flutter and the risk of thromboembolism: a systematic review and meta-analysis. Am J Med 2005; 118:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/11\">",
"      Arnold AZ, Mick MJ, Mazurek RP, et al. Role of prophylactic anticoagulation for direct current cardioversion in patients with atrial fibrillation or atrial flutter. J Am Coll Cardiol 1992; 19:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/12\">",
"      Chalasani P, Cambre S, Silverman ME. Direct-current cardioversion for the conversion of atrial flutter. Am J Cardiol 1996; 77:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/13\">",
"      Mehta D, Baruch L. Thromboembolism following cardioversion of \"common\" atrial flutter. Risk factors and limitations of transesophageal echocardiography. Chest 1996; 110:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/14\">",
"      Elhendy A, Gentile F, Khandheria BK, et al. Thromboembolic complications after electrical cardioversion in patients with atrial flutter. Am J Med 2001; 111:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/15\">",
"      Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002; 40:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/16\">",
"      Seidl K, Hauer B, Schwick NG, et al. Risk of thromboembolic events in patients with atrial flutter. Am J Cardiol 1998; 82:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/17\">",
"      Lanzarotti CJ, Olshansky B. Thromboembolism in chronic atrial flutter: is the risk underestimated? J Am Coll Cardiol 1997; 30:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/18\">",
"      Jordaens L, Missault L, Germonpr&eacute; E, et al. Delayed restoration of atrial function after conversion of atrial flutter by pacing or electrical cardioversion. Am J Cardiol 1993; 71:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/19\">",
"      Sparks PB, Jayaprakash S, Vohra JK, et al. Left atrial \"stunning\" following radiofrequency catheter ablation of chronic atrial flutter. J Am Coll Cardiol 1998; 32:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/20\">",
"      Welch PJ, Afridi I, Joglar JA, et al. Effect of radiofrequency ablation on atrial mechanical function in patients with atrial flutter. Am J Cardiol 1999; 84:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/21\">",
"      Granada J, Uribe W, Chyou PH, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/22\">",
"      Garson A Jr, Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in the young: a collaborative study of 380 cases. J Am Coll Cardiol 1985; 6:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/23\">",
"      Halligan SC, Gersh BJ, Brown RD Jr, et al. The natural history of lone atrial flutter. Ann Intern Med 2004; 140:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/24\">",
"      Silverman DI, Manning WJ. Prophylactic anticoagulation of atrial flutter prior to cardioversion: meeting the \"burden of proof\". Am J Med 2001; 111:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/25\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/26\">",
"      Olshansky B. High intensity anticoagulation for cardioversion of atrial arrhythmias? The shocking truth. J Am Coll Cardiol 2002; 40:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/27\">",
"      Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001; 344:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/28\">",
"      Stoddard MF, Dawkins PR, Prince CR, Longaker RA. Transesophageal echocardiographic guidance of cardioversion in patients with atrial fibrillation. Am Heart J 1995; 129:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/29\">",
"      Black IW, Hopkins AP, Lee LC, Walsh WF. Evaluation of transesophageal echocardiography before cardioversion of atrial fibrillation and flutter in nonanticoagulated patients. Am Heart J 1993; 126:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/30\">",
"      Black IW, Fatkin D, Sagar KB, et al. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation. A multicenter study. Circulation 1994; 89:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37511/abstract/31\">",
"      Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1066 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-197.136.42.3-FBD08E2E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37511=[""].join("\n");
var outline_f36_40_37511=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H190086348\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THROMBI IN ATRIAL FLUTTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EMBOLIC RISK RELATED TO CARDIOVERSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Atrial stunning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EMBOLIC RISK IN CHRONIC ATRIAL FLUTTER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lone atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RECOMMENDATIONS FOR ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Relation to cardioversion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - High thromboembolic risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Low thromboembolic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chronic or recurrent atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190086348\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1066\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1066|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/12/22734\" title=\"figure 1\">",
"      Atrial flutter stroke risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1066|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/45/40668\" title=\"table 1\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24888?source=related_link\">",
"      Maintenance of sinus rhythm after cardioversion in atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_40_37512="Acyclovir (systemic): Drug information";
var content_f36_40_37512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acyclovir (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/48/38660?source=see_link\">",
"    see \"Acyclovir (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/37/2649?source=see_link\">",
"    see \"Acyclovir (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7808291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7808292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Acyclovir&reg;;",
"     </li>",
"     <li>",
"      Mylan-Acyclovir;",
"     </li>",
"     <li>",
"      Nu-Acyclovir;",
"     </li>",
"     <li>",
"      ratio-Acyclovir;",
"     </li>",
"     <li>",
"      Teva-Acyclovir;",
"     </li>",
"     <li>",
"      Zovirax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7912017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7901185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Obese patients should be dosed using ideal body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Genital herpes simplex virus (HSV) infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Immunocompetent: Initial episode, severe: 5 mg/kg/dose every 8 hours for 5-7 days",
"     <b>",
"      or",
"     </b>",
"     5-10 mg/kg/dose every 8 hours for 2-7 days, follow with oral therapy to complete at least 10 days of therapy (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Initial episode: 200 mg 5 times daily for 10 days",
"     <b>",
"      or",
"     </b>",
"     400 mg 3 times daily for 7-10 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Recurrence: 200 mg 5 times daily for 5 days (per manufacturer's labeling; begin at earliest signs of disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternatively, the following regimens are also recommended by the CDC: 400 mg 3 times daily for 5 days; 800 mg twice daily for 5 days;  800 mg 3 times daily for 2 days (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chronic suppression: 400 mg twice daily or 200 mg 3-5 times daily, for up to 12 months followed by re-evaluation (per manufacturer's labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Herpes zoster (shingles):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Immunocompetent: 800 mg 5 times daily for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Immunocompromised: 10 mg/kg/dose or 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HSV encephalitis:",
"     </b>",
"     I.V.: 10 mg/kg/dose every 8 hours for 10 days (per manufacturer's labeling); 10-15 mg/kg/dose every 8 hours for 14-21 days also reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mucocutaneous HSV:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Immunocompromised: Treatment: 5 mg/kg/dose every 8 hours for 7 days (Leflore, 2000); dosing for up to 14 days also reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral (unlabeled use): Immunocompromised: 400 mg 5 times daily for 7 days (Leflore, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Orolabial HSV (unlabeled use):",
"     </b>",
"     Oral (immunocompetent):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 200-400 mg 5 times daily for 5 days (Cernik, 2008;  Leflore, 2000; Spruance, 1990) for episodic/recurrent treatment; for initial treatment, limited data are available, 200 mg 5 times daily or 400 mg 3 times daily for 7-10 days has been recommended by some clinicians.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic suppression: 400 mg 2 times daily (has been clinically evaluated for up to 1 year) (Cernik, 2008; Rooney, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Varicella-zoster (chickenpox):",
"     </b>",
"     Begin treatment within the first 24 hours of rash onset:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: &gt;40 kg (immunocompetent): 800 mg 4 times daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Manufacturer&rsquo;s labeling (immunocompromised):",
"     </i>",
"     10 mg/kg/dose every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      CDC HIV guidelines (immunocompromised):",
"     </i>",
"     10-15 mg/kg/dose every 8 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of HSV reactivation in HIV-positive patients (unlabeled use):",
"     </b>",
"     Oral: 400-800 mg 2-3 times daily (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of HSV reactivation in HSCT (unlabeled use):",
"     </b>",
"     <i>",
"      CDC recommendation:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Start at the beginning of conditioning therapy and continue until engraftment or until mucositis resolves (~30 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 200 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of VZV reactivation in allogeneic HSCT (unlabeled use):",
"     </b>",
"     <i>",
"      NCCN guidelines:",
"     </i>",
"     Oral: 800 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of CMV reactivation in low-risk allogeneic HSCT (unlabeled use):",
"     </b>",
"     <i>",
"      NCCN guidelines:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Requires close monitoring (due to weak activity); not for use in patients at high risk for CMV disease: Oral: 800 mg 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Treatment of disseminated HSV or VZV or empiric treatment of suspected encephalitis in immunocompromised patients with cancer: (unlabeled use):",
"     </b>",
"     <i>",
"      NCCN guidelines:",
"     </i>",
"     I.V.: 10-12 mg/kg/dose every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of episodic HSV infection in HIV-positive patient (unlabeled use):",
"     </b>",
"     Oral: 400 mg 3 times daily for 5-10 days (CDC, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7901184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/37/2649?source=see_link\">",
"      see \"Acyclovir (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Obese patients should be dosed using ideal body weight",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Genital herpes simplex virus (HSV) infection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immunocompetent:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial episode (unlabeled use): 40-80 mg/kg/day divided into 3-4 doses for 5-10 days (maximum: 1000 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Chronic suppression (unlabeled use; limited data): 80 mg/kg/day in 3 divided doses (maximum: 1000 mg daily), re-evaluate after 12 months of treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Immunocompromised (unlabeled use; CDC, 2009): Initial episode:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &lt;45 kg: 60 mg/kg/day divided into 3 doses for 5-14 days (maximum: 1200 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents: 400 mg twice daily for 5-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Herpes zoster (shingles):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years (immunocompromised): 20 mg/kg/dose every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      HSV encephalitis:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 3 months to 12 years: 20 mg/kg/dose every 8 hours for 10 days (per manufacturer's labeling); dosing for 14-21 days also reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mucocutaneous HSV:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years (immunocompromised): Treatment: 10 mg/kg/dose every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years (immunocompromised): Treatment: 5-10 mg/kg/dose every 8 hours for 7 days (Leflore, 2000); dosing for up to 14 days also reported",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neonatal HSV:",
"     </b>",
"     I.V.: Infants: Birth to 3 months: 10 mg/kg/dose every 8 hours for 10 days (manufacturer's labeling); 20 mg/kg/dose every 8 hours for 14 (skin and mucous membrane disease) to 21 days (CNS disease) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Orolabial HSV (unlabeled use):",
"     </b>",
"     Oral: Children 1-6 years (immunocompetent, gingivostomatitis): Treatment of primary infection: 15 mg/kg/dose (maximum: 200 mg per dose) 5 times daily for 7 days, initiated within 72 hours of symptom onset (Amir, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Varicella-zoster (chickenpox):",
"     </b>",
"     Begin treatment within the first 24 hours of rash onset:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     The CDC HIV guidelines recommended duration of therapy is 7-10 days or until no new lesions for 48 hours (for patients with mild varicella and no or moderate immune suppression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;2 years and &le;40 kg (immunocompetent): 20 mg/kg/dose (maximum: 800 mg per dose) 4 times daily for 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;40 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling (immunocompromised):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &lt;12 years: 20 mg/kg/dose every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;12 years: 10 mg/kg/dose every 8 hours for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     CDC HIV guidelines (immunocompromised):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &lt;1 year: 10 mg/kg/dose every 8 hours for 7-10 days or until no new lesions for 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;1 year: 10 mg/kg/dose or 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 8 hours for 7-10 days or until no new lesions for 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Varicella-zoster acute retinal necrosis infection in HIV-exposed/-positive patients (unlabeled use; CDC, 2009):",
"     </b>",
"     I.V.: Infants and Children: 10-15 mg/kg/dose every 8 hours for 10-14 days, followed by valacyclovir for 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of HSV reactivation in HIV-exposed/-positive patients (unlabeled use; CDC, 2009):",
"     </b>",
"     Oral: 20 mg/kg/dose twice daily (maximum: 400 mg per dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of HSV reactivation in HSCT (unlabeled use):",
"     </b>",
"     <i>",
"      CDC recommendation:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Start at the beginning of conditioning therapy and continue until engraftment or until mucositis resolves (~30 days): I.V.: 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 8 hours or 125 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7901186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7901187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Normal dosing regimen 800 mg 5 times daily: Administer 800 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Normal dosing regimen 200 mg 5 times daily or 400 mg every 12 hours: Administer 200 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Normal dosing regimen 800 mg 5 times daily: Administer 800 mg every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     25-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer recommended dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-25 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer recommended dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer 50% of recommended dose every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intermittent hemodialysis (IHD) (administer after hemodialysis on dialysis days): Dialyzable (60% reduction following a 6-hour session): I.V.: 2.5-5 mg/kg every 24 hours (Heintz, 2009).",
"     <b>",
"      Note:",
"     </b>",
"     Dosing dependent on the assumption of 3 times weekly, complete IHD sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis (PD): Administer 50% of normal dose once daily; no supplemental dose needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT) (Heintz, 2009; Trotman, 2005): Drug clearance is highly dependent on the method of renal replacement, filter type, and flow rate. Appropriate dosing requires close monitoring of pharmacologic response, signs of adverse reactions due to drug accumulation, as well as drug concentrations in relation to target trough (if appropriate). The following are general recommendations only (based on dialysate flow/ultrafiltration rates of 1-2 L/hour and minimal residual renal function) and should not supersede clinical judgment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVH: I.V.: 5-10 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CVVHD/CVVHDF: I.V.: 5-10 mg/kg every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     The higher end of dosage range (eg, 10 mg/kg every 12 hours for CVVHDF) is recommended for viral meningoencephalitis and varicella-zoster virus infections.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral, I.V.: No dosage adjustment provided in manufacturer's labeling; use caution in patients with severe impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7901193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]: 500 mg, 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [strength expressed as base, preservative free]: 50 mg/mL (10 mL, 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 200 mg/5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 200 mg/5 mL (473 mL) [banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 400 mg, 800 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zovirax&reg;: 400 mg, 800 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7908323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7808318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Avoid rapid infusion; infuse over 1 hour to prevent renal damage; maintain adequate hydration of patient; check for phlebitis and rotate infusion sites. Avoid I.M. or SubQ administration.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F7808315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Incompatible",
"     </b>",
"     with blood products and protein-containing solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Allopurinol, amikacin, amphotericin B cholesteryl sulfate complex, ampicillin, anidulafungin, cefazolin, cefotaxime, cefoxitin, ceftazidime, cefuroxime,  chloramphenicol, cimetidine, clindamycin,  dexamethasone sodium phosphate, dimenhydrinate, docetaxel, doripenem, doxorubicin liposome, doxycycline, droperidol, erythromycin lactobionate, etoposide phosphate, famotidine, fentanyl, filgrastim, fluconazole, gallium nitrate, heparin, hydrocortisone sodium succinate, hydromorphone, imipenem/cilastatin, linezolid, lorazepam, magnesium sulfate, melphalan, methylprednisolone sodium succinate, metronidazole, milrinone, multivitamins, nafcillin, nalbuphine, oxacillin, paclitaxel, pemetrexed, penicillin G potassium, pentobarbital, piperacillin, potassium chloride, propofol, ranitidine, remifentanil, sodium bicarbonate, sulfamethoxazole and trimethoprim, teniposide, theophylline, thiotepa, tobramycin, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amifostine, amsacrine, aztreonam, caffeine citrate, cefepime, cyclosporine, dobutamine, dopamine, fludarabine, foscarnet, gemcitabine, idarubicin, levofloxacin, ondansetron, pantoprazole, piperacillin/tazobactam, sargramostim, TrophAmine&reg;, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Caspofungin, cefepime, ceftriaxone, cisatracurium, diltiazem, diphenhydramine, gentamicin, granisetron, meperidine, meropenem, metoclopramide, morphine, tacrolimus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Caffeine citrate, ceftriaxone, pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7908324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of genital herpes simplex virus (HSV) and HSV encephalitis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7908325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of HSV reactivation in HIV-positive patients; prevention of HSV reactivation in hematopoietic stem cell transplant (HSCT); prevention of HSV reactivation during periods of neutropenia in patients with cancer; prevention of varicella zoster virus (VZV) reactivation in allogenic HSCT; prevention of CMV reactivation in low-risk allogeneic HSCT; treatment of disseminated HSV or VZV in immunocompromised patients with cancer; empiric treatment of suspected encephalitis in immunocompromised patients with cancer; treatment of initial and prophylaxis of recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) infections in immunocompromised patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7808290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acyclovir may be confused with ganciclovir, Retrovir&reg;, valacyclovir",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zovirax&reg; may be confused with Doribax&reg;, Valtrex&reg;, Zithromax&reg;, Zostrix&reg;, Zyloprim&reg;, Zyvox&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7808309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Malaise (&le;12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2% to 5%), vomiting (&le;3%), diarrhea (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parenteral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hives (2%), itching (2%), rash  (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Inflammation at injection site or phlebitis (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (5% to 10%), creatinine increased (5% to 10%), acute renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      All forms:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, aggression, agitation, anemia, anorexia, ataxia, coma, confusion, consciousness decreased, delirium, desquamation, disseminated intravascular coagulopathy (DIC), dizziness, dysarthria, encephalopathy, fatigue, fever, gastrointestinal distress, hallucinations, hematuria, hemolysis, hepatitis, hyperbilirubinemia, hypotension, insomnia, jaundice, leukocytoclastic vasculitis, leukocytosis, leukopenia, lymphadenopathy, mental depression, myalgia, neutrophilia, pain, psychosis, renal failure, renal pain, seizure, somnolence, sore throat, thrombocytopenia, thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), thrombocytosis, visual disturbances",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7901079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7908330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal effects: Renal failure (sometimes fatal) has been reported. Dehydration, pre-existing renal disease and nephrotoxic drugs increase risk; infuse over at least 1 hour to reduce risk of renal tubular damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Has been reported in immunocompromised patients receiving acyclovir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with pre-existing renal impairment; dosage adjustments recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Varicella-zoster: Appropriate use: Treatment should begin within 24 hours of appearance of rash; oral route not recommended for routine use in otherwise healthy children with varicella, but may be effective in patients at increased risk of moderate-to-severe infection (&gt;12 years of age, chronic cutaneous or pulmonary disorders, long-term salicylate therapy, corticosteroid therapy).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrotoxic drugs: Use with caution in patients receiving other nephrotoxic drugs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection: Use I.V. preparation with caution in patients with underlying neurologic abnormalities, serious hepatic or electrolyte abnormalities, or substantial hypoxia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adequate hydration: Maintain adequate hydration during oral or intravenous therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7911154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May increase the serum concentration of Acyclovir-Valacyclovir. Acyclovir-Valacyclovir may increase the serum concentration of Mycophenolate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: Acyclovir-Valacyclovir may decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Acyclovir-Valacyclovir may enhance the CNS depressant effect of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zoster Vaccine: Acyclovir-Valacyclovir may diminish the therapeutic effect of Zoster Vaccine.  Management: When possible, discontinue antiviral agents with anti-zoster activity (i.e., acyclovir, valacyclovir, famciclovir) for at least 24 hours prior to and 14 days after receiving a live attenuated zoster vaccine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F7912074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Does not affect absorption of oral acyclovir.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7908326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7908327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Acyclovir has been shown to cross the human placenta (Henderson, 1992). Results from a pregnancy registry, established in 1984 and closed in 1999, did not find an increase in the number of birth defects with exposure to acyclovir when compared to those expected in the general population. However, due to the small size of the registry and lack of long-term data, the manufacturer recommends using during pregnancy with caution and only when clearly needed. Acyclovir may be appropriate for the treatment of genital herpes in pregnant women (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7908329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use with caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7901078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acyclovir is excreted in breast milk. The manufacturer recommends that caution be exercised when administering acyclovir to nursing women. Limited data suggest exposure to the nursing infant of ~0.3 mg/kg/day following oral administration of acyclovir to the mother. Nursing mothers with herpetic lesions near or on the breast should avoid breast-feeding (Gartner, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F7901189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7912078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Acyclovir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $97.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Zovirax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $380.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acyclovir Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (10 mL): $18.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Acyclovir Sodium Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $5.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (1): $10.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Acyclovir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/5 mL (473 mL): $137.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Zovirax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg/5 mL (473 mL): $314.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Acyclovir Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $216.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (100): $421.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Zovirax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $737.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     800 mg (100): $1434.53",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7908384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Urinalysis, BUN, serum creatinine, liver enzymes, CBC",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acic (EE);",
"     </li>",
"     <li>",
"      Aciclodan (DK);",
"     </li>",
"     <li>",
"      Aciclor (VE);",
"     </li>",
"     <li>",
"      Aciclosina (PT);",
"     </li>",
"     <li>",
"      Acicvir (NZ);",
"     </li>",
"     <li>",
"      Aciherpin (PH);",
"     </li>",
"     <li>",
"      Acihexal (AU);",
"     </li>",
"     <li>",
"      Acivir Eye (IN);",
"     </li>",
"     <li>",
"      Acivirex (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Aclovir (FI, TH, TW);",
"     </li>",
"     <li>",
"      ACS (KP);",
"     </li>",
"     <li>",
"      Activir (FR);",
"     </li>",
"     <li>",
"      Acyclo-V (AU, BH);",
"     </li>",
"     <li>",
"      Acyclovenir (IL);",
"     </li>",
"     <li>",
"      Acylene (MY);",
"     </li>",
"     <li>",
"      Acyrax (FI);",
"     </li>",
"     <li>",
"      Acyvir (EC, IT);",
"     </li>",
"     <li>",
"      Aisike (CL);",
"     </li>",
"     <li>",
"      Aisile (CL);",
"     </li>",
"     <li>",
"      Antix (NO);",
"     </li>",
"     <li>",
"      Asile (CL);",
"     </li>",
"     <li>",
"      Avir (VE);",
"     </li>",
"     <li>",
"      Avorax (HK);",
"     </li>",
"     <li>",
"      Bearax (SG);",
"     </li>",
"     <li>",
"      Biraxin (PH);",
"     </li>",
"     <li>",
"      Cicloferon (CR, DO, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Cicloviral (CO);",
"     </li>",
"     <li>",
"      Ciclox (PH);",
"     </li>",
"     <li>",
"      Clinovir (ID, TH);",
"     </li>",
"     <li>",
"      Clopes (ID);",
"     </li>",
"     <li>",
"      Clovika (ID);",
"     </li>",
"     <li>",
"      Clovir (KP, PH);",
"     </li>",
"     <li>",
"      Covelay (PH);",
"     </li>",
"     <li>",
"      Cusiviral (MY, SG);",
"     </li>",
"     <li>",
"      Cyclivex (ZA);",
"     </li>",
"     <li>",
"      Cycloherp (HK);",
"     </li>",
"     <li>",
"      Cyclostad (PH);",
"     </li>",
"     <li>",
"      Cyclovir (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Cyllanvir (PH);",
"     </li>",
"     <li>",
"      Deherp (TH, TW);",
"     </li>",
"     <li>",
"      Docaciclo (BE);",
"     </li>",
"     <li>",
"      Dravyr (MY, SG);",
"     </li>",
"     <li>",
"      Duvimex (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ecuvir (EC);",
"     </li>",
"     <li>",
"      Entir (SG, TH);",
"     </li>",
"     <li>",
"      Erlvirax (SG);",
"     </li>",
"     <li>",
"      Euroclovir (HK);",
"     </li>",
"     <li>",
"      Eurovir (PY);",
"     </li>",
"     <li>",
"      Expit (UY);",
"     </li>",
"     <li>",
"      Geavir (DK, SE);",
"     </li>",
"     <li>",
"      Helvevir (CH);",
"     </li>",
"     <li>",
"      Herax (ID);",
"     </li>",
"     <li>",
"      Herpesin (CZ);",
"     </li>",
"     <li>",
"      Herpetad (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Herpevex (MY);",
"     </li>",
"     <li>",
"      Herpevir (FR);",
"     </li>",
"     <li>",
"      Herpex (BH, IN, PH);",
"     </li>",
"     <li>",
"      Herpizyg (TH);",
"     </li>",
"     <li>",
"      Heviran (PL);",
"     </li>",
"     <li>",
"      Lermex (TH);",
"     </li>",
"     <li>",
"      Licovir (ID);",
"     </li>",
"     <li>",
"      Lisovyr (AR, CN);",
"     </li>",
"     <li>",
"      Lovir (AU, NZ, PH);",
"     </li>",
"     <li>",
"      Lovire (ZA);",
"     </li>",
"     <li>",
"      Marvir (TH);",
"     </li>",
"     <li>",
"      Medovir (AE, BF, BG, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SA, SC, SD, SG, SL, SN, SY, TN, TW, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Molavir (ID);",
"     </li>",
"     <li>",
"      Norum (TH);",
"     </li>",
"     <li>",
"      Ozvir (AU);",
"     </li>",
"     <li>",
"      Poviral (AR);",
"     </li>",
"     <li>",
"      Qualiclovir (HK);",
"     </li>",
"     <li>",
"      Ranvir (TH);",
"     </li>",
"     <li>",
"      Reclovax (TH);",
"     </li>",
"     <li>",
"      Remex (FR);",
"     </li>",
"     <li>",
"      Skirax (TW);",
"     </li>",
"     <li>",
"      Vacrax (MY);",
"     </li>",
"     <li>",
"      Vermis (TH);",
"     </li>",
"     <li>",
"      Viralex-DS (PH);",
"     </li>",
"     <li>",
"      Viratop (BE);",
"     </li>",
"     <li>",
"      Virax (KP);",
"     </li>",
"     <li>",
"      Virest (HK, SG);",
"     </li>",
"     <li>",
"      Virex (CO);",
"     </li>",
"     <li>",
"      Virless (MY, SG, TW);",
"     </li>",
"     <li>",
"      Viroclear (HK);",
"     </li>",
"     <li>",
"      Virogon (TH);",
"     </li>",
"     <li>",
"      Viromed (TH);",
"     </li>",
"     <li>",
"      Virzin (DE);",
"     </li>",
"     <li>",
"      Vivir (KP);",
"     </li>",
"     <li>",
"      Zevin (TH);",
"     </li>",
"     <li>",
"      Zodiac (KP);",
"     </li>",
"     <li>",
"      Zoral (HK, MY, SG);",
"     </li>",
"     <li>",
"      Zorax (SG);",
"     </li>",
"     <li>",
"      Zorexin (MY);",
"     </li>",
"     <li>",
"      Zoter (ID);",
"     </li>",
"     <li>",
"      Zoteran (PH);",
"     </li>",
"     <li>",
"      Zovir (DK);",
"     </li>",
"     <li>",
"      Zovirax (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BO, BR, BS, CH, CI, CN, CR, CY, CZ, DO, EC, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, ID, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SK, SL, SN, SV, SY, TN, TR, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Zoylex (PE);",
"     </li>",
"     <li>",
"      Zyvir (KE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7908334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acyclovir is converted to acyclovir monophosphate by virus-specific thymidine kinase then further converted to acyclovir triphosphate by other cellular enzymes. Acyclovir triphosphate inhibits DNA synthesis and viral replication by competing with deoxyguanosine triphosphate for viral DNA polymerase and being incorporated into viral DNA.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7808316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 15% to 30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.8 L/kg (63.6 L): Widely (eg, brain, kidney, lungs, liver, spleen, muscle, uterus, vagina, CSF)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 9% to 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Converted by viral enzymes to acyclovir monophosphate, and further converted to diphosphate then triphosphate (active form) by cellular enzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 10% to 20% with normal renal function (bioavailability decreases with increased dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Neonates: 4 hours; Children 1-12 years: 2-3 hours; Adults: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral: Within 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (62% to 90% as unchanged drug and metabolite)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;The Use of Oral Acyclovir in Otherwise Healthy Children With Varicella,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 91(3):674-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/8382784/pubmed\" id=\"8382784\" target=\"_blank\">",
"        8382784",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Amir J, Harel L, Smetana Z, et al, &ldquo;Treatment of Herpes Simplex Gingivostomatitis With Aciclovir in Children: A Randomised, Double Blind Placebo Controlled Study,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      1997, 314(7097):1800-3. Available at file://www.bmj.com/content/314/7097/1800.full?sid=22b276f2-5ca8-4aae-8d10-2a4a299772bc",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/9224082/pubmed\" id=\"9224082\" target=\"_blank\">",
"        9224082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeckh M, Kim HW, Flowers ME, et al, &ldquo;Long-Term Acyclovir for Prevention of Varicella Zoster Virus Disease After Allogeneic Hematopoietic Cell Transplantation- A Randomized Double-Blind Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 107(5):1800-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/16282339/pubmed\" id=\"16282339\" target=\"_blank\">",
"        16282339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients: Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2000, 49(RR-10):1-112. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr4910a1.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cernik C, Gallina K, and Brodell RT, &ldquo;The Treatment of Herpes Simplex Infections: An Evidence-Based Review,&rdquo;",
"      <i>",
"       Arch Int Med",
"      </i>",
"      , 2008, 168(11):1137-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/18541820/pubmed\" id=\"18541820\" target=\"_blank\">",
"        18541820",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dunkle LM, Arvin AM, Whitley RJ, et al, &ldquo;A Controlled Trial of Acyclovir for Chickenpox in Normal Children,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 325(22):1539-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/1944438/pubmed\" id=\"1944438\" target=\"_blank\">",
"        1944438",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eck P, Silver SM, and Clark EC, &ldquo;Acute Renal Failure and Coma After a High Dose of Oral Acyclovir,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 325(16):1178-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/1891032/pubmed\" id=\"1891032\" target=\"_blank\">",
"        1891032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eisen D, Essell J, Broun ER, et al, &ldquo;Clinical Utility of Oral Valacyclovir Compared With Oral Acyclovir for the Prevention of Herpes Simplex Virus Mucositis Following Autologous Bone Marrow Transplantation or Stem Cell Rescue Therapy,&rdquo;",
"      <i>",
"       Bone Marrow Transplant",
"      </i>",
"      , 2003, 31(1):51-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/12621507/pubmed\" id=\"12621507\" target=\"_blank\">",
"        12621507",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Englund JA, Fletcher CV, and Balfour HH Jr, &ldquo;Acyclovir Therapy in Neonates,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 119(1 Pt 1):129-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/2066845/pubmed\" id=\"2066845\" target=\"_blank\">",
"        2066845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gartner LM, Morton J, Lawrence RA, et al, \"Breastfeeding and the Use of Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 115(2):496-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/15687461/pubmed\" id=\"15687461\" target=\"_blank\">",
"        15687461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Henderson GI, Hu ZQ, Johnson RF, et al, \"Acyclovir Transport by the Human Placenta,\"",
"      <i>",
"       J Lab Clin Med",
"      </i>",
"      , 1992, 120(6):885-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/1453110/pubmed\" id=\"1453110\" target=\"_blank\">",
"        1453110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leflore S, Anderson PL, and Fletcher CV.  &ldquo;A Risk-Benefit Evaluation of Aciclovir for the Treatment and Prophylaxis of Herpes Simplex Virus Infections,&rdquo;",
"      <i>",
"       Drug Safety",
"      </i>",
"      , 2000, 23(2):131-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/10945375/pubmed\" id=\"10945375\" target=\"_blank\">",
"        10945375",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prevention and Treatment of Cancer-Related Infections,&rdquo; Version 1.2008. Available at   file://www.nccn.org/professionals/physician_gls/PDF/infections.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Novelli VM, Marshall WC, Yeo J, et al, &ldquo;High-Dose Oral Acyclovir for Children at Risk of Disseminated Herpesvirus Infections,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1985, 151(2):372.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/2981940/pubmed\" id=\"2981940\" target=\"_blank\">",
"        2981940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raborn GW, Martel AY, Grace MG, et al, &ldquo;Oral Acyclovir in Prevention of Herpes Labialis. A Randomized, Double-Blind, Multi-Centered Clinical Trial,&rdquo;",
"      <i>",
"       Oral Surg Oral Med Oral Pathol Oral Radiol Endod",
"      </i>",
"      , 1998, 85(1):55-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/9474615/pubmed\" id=\"9474615\" target=\"_blank\">",
"        9474615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rayani SA, Nimmo CJ, Frighetto L, et al, &ldquo;Implementation and Evaluation of a Standardized Herpes Simplex Virus Prophylaxis Protocol on a Leukemia/Bone Marrow Transplant Unit,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(7-8):852-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/7949499/pubmed\" id=\"7949499\" target=\"_blank\">",
"        7949499",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rooney JF, Straus SE, Mannix ML, et al, &ldquo;Oral Acyclovir to Suppress Frequently Recurrent Herpes Labialis. A Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1993, 118(4):268-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/8380540/pubmed\" id=\"8380540\" target=\"_blank\">",
"        8380540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spruance SL, Hamill ML, Hoge WS, et al, &ldquo;Acyclovir Prevents Reactivation of Herpes Simplex Labialis in Skiers,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1988, 260(11):1597-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/3411740/pubmed\" id=\"3411740\" target=\"_blank\">",
"        3411740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spruance SL, Stewart JCB, Rowe NH, et al, &ldquo;Treatment of Recurrent Herpes Simplex Labialis With Oral Acyclovir,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1990, 161(2):185-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/2153735/pubmed\" id=\"2153735\" target=\"_blank\">",
"        2153735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trotman RL, Williamson JC, Shoemaker DM, et al, \"Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2005, 41(8):1159-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/16163635/pubmed\" id=\"16163635\" target=\"_blank\">",
"        16163635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wade JC, Newton B, Flournoy N, et al, &ldquo;Oral Acyclovir for Prevention of Herpes Simplex Virus Reactivation After Marrow Transplantation,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1984, 100(6):823-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/6326632/pubmed\" id=\"6326632\" target=\"_blank\">",
"        6326632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wood MJ, Johnson RW, McKendrick MW, et al, &ldquo;A Randomized Trial of Acyclovir for 7 Days or 21 Days With and Without Prednisolone for Treatment of Acute Herpes Zoster,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(13):896-900.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?36/40/37512/abstract-text/8114860/pubmed\" id=\"8114860\" target=\"_blank\">",
"        8114860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8628 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37512=[""].join("\n");
var outline_f36_40_37512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808291\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808292\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912017\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901185\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901184\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901186\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901187\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671282\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901193\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908323\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808318\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808315\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908324\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908325\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808290\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808309\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901079\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908330\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298682\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7911154\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912074\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908326\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908327\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908329\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901078\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7901189\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7912078\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908384\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961951\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7908334\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7808316\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8628\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8628|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"mobipreview.htm?17/42/18081?source=related_link\">",
"      Acyclovir (ophthalmic): International drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/48/38660?source=related_link\">",
"      Acyclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/37/2649?source=related_link\">",
"      Acyclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?1/27/1460?source=related_link\">",
"      Acyclovir (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/60/40899?source=related_link\">",
"      Acyclovir (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/51/9011?source=related_link\">",
"      Acyclovir (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_40_37513="Diagnosis and treatment of adenovirus infection";
var content_f36_40_37513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and treatment of adenovirus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Flor M Munoz, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Phyllis Flomenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?36/40/37513/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?36/40/37513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses are a family of DNA viruses that are an important cause of febrile illnesses in young children. They are most frequently associated with upper respiratory tract syndromes such as pharyngitis or coryza, but can also cause pneumonia. Less commonly, adenoviruses cause gastrointestinal, ophthalmologic, genitourinary, neurologic, and disseminated disease. Most adenoviral diseases are self-limiting, although fatal infections can occur in immunocompromised hosts and occasionally in healthy children and adults.",
"   </p>",
"   <p>",
"    The available diagnostic tests and strategies for treatment and prevention of adenovirus infection will be reviewed here. The virology, epidemiology, and clinical manifestations of adenovirus infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18818874\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since adenoviruses are associated with a variety of clinical syndromes and non-specific manifestations, diagnosis based upon clinical criteria alone is challenging. The diagnosis of adenovirus disease should be confirmed in outbreaks of infection and in individual patients with serious disease manifestations. Confirmation of adenovirus infection is important in order to decide on the use of antiviral agents, exclude other treatable infections, establish a prognosis, and initiate infection control measures when appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different approaches are available for the specific diagnosis of adenovirus infection (",
"    <a class=\"graphic graphic_table graphicRef59727 \" href=\"mobipreview.htm?5/48/5901\">",
"     table 1",
"    </a>",
"    ). Viral culture, adenovirus-specific viral antigen assays, and polymerase chain reaction assays are used most frequently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Viral culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;All adenovirus serotypes except types 40 and 41 cause a characteristic cytopathic effect (CPE) in human epithelial cell lines such as HeLa, A549, or HEp2, and in primary human embryonic kidney (HEK) cells. CPE generally occurs within two to seven days with the common lower serotypes, but some others, especially subgroup D serotypes (which cause epidemic keratoconjunctivitis), can require up to 28 days.",
"   </p>",
"   <p>",
"    Adenoviruses are relatively stable and can be readily recovered from clinical samples early in the course of the disease. Appropriate samples include nasopharyngeal swabs or aspirates, throat swabs or washes, sputum, tracheal aspirates, bronchoalveolar lavage fluid, conjunctival swabs or scrapings, stool or rectal swabs, urine, cerebrospinal fluid (CSF), and tissue samples. Swabs and tissue biopsies should be placed in a viral transport medium to prevent drying and inhibit bacterial overgrowth. Specimens should be transported to the laboratory on ice. The duration of viral excretion at the time of acute disease is approximately one to three days from throat in adults with upper respiratory infection; three to five days from nose, throat, and eye in patients with pharyngoconjunctival fever; and two weeks from eye cultures in patients with keratoconjunctivitis.",
"   </p>",
"   <p>",
"    After acute infection, adenoviruses may be intermittently excreted from stool (or throat less commonly) for months in some patients. In immunocompromised hosts, adenoviruses may be continuously shed from stool or urine for months without symptoms. Therefore, a positive culture result needs to be interpreted based upon the current clinical manifestations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Viral antigen assay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct detection of adenovirus antigens in clinical samples may be performed by an adenovirus-specific enzyme-linked immunosorbent assay (EIA) or immunofluorescence assay. These assays are more rapid, but less sensitive than viral culture for the detection of most serotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/1\">",
"     1",
"    </a>",
"    ]. They are insufficiently sensitive for diagnosis in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Commercially available assays use adenovirus-specific monoclonal antibodies that react with common antigenic determinants on all serotypes. In particular, antigen assays are the test of choice for the detection of the fastidious adenovirus types 40 and 41 in stool samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/3\">",
"     3",
"    </a>",
"    ]. These enteric adenoviruses are an important cause of diarrhea in infants.",
"   </p>",
"   <p>",
"    Another potential application for direct antigen assays is in the rapid diagnosis of epidemic keratoconjunctivitis (EKC). The Adenoclone-EIA (Cambridge Biotech) was evaluated as a rapid diagnostic test for adenoviral ocular infection applied to conjunctival swabs from 372 culture-positive infected eyes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/4\">",
"     4",
"    </a>",
"    ]. The overall sensitivity of the EIA was only 38 percent, but in swabs obtained within the first week of illness, the sensitivity improved to 65 percent. Therefore, this assay may be a useful adjunct to routine viral culture early in the course of the illness.",
"   </p>",
"   <p>",
"    Direct adenovirus antigen assays can also be used to screen cell cultures before the development of CPE, as well as to confirm the presence of adenovirus in cell cultures positive for CPE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Polymerase chain reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) is a highly sensitive and specific assay that can be used to detect adenovirus DNA from a variety of clinical specimens including fixed tissues. PCR is particularly helpful in samples from normally sterile sites such as blood, CSF, and tissues. A positive result from upper respiratory tract or stool samples is more difficult to interpret as it may represent virus shedding rather than symptomatic infection. Therefore, PCR results must be interpreted in the context of the clinical findings of adenovirus disease. Because different adenovirus serotypes are heterogeneous at the DNA level, PCR primers may be selected to detect specific serotypes or related serotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/5\">",
"     5",
"    </a>",
"    ]. Commercial adenovirus PCR assays use universal primers and probes that detect most or all serotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detection of adenovirus DNA in the blood by quantitative PCR is increasingly utilized for the evaluation of adenovirus infections in immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Studies have demonstrated an association between rising viremia and the risk of both invasive disease and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In addition, quantification of adenovirus DNA can be used to assess response to antiviral treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In one study, a greater than 10-fold decrease in viral load one week after the first dose of antiviral therapy was associated with a favorable clinical course, whereas all patients with fatal disease failed to show a significant reduction in viral load [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/11\">",
"     11",
"    </a>",
"    ]. PCR can also be used in conjunction with sequencing in order to rapidly genotype adenovirus isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H18818704\">",
"     'Serotyping and genotyping'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    PCR has been used to diagnose adenovirus myocarditis. Routine viral cultures and histopathology are rarely positive in cases of presumed viral myocarditis. In one study, 38 myocardial tissue samples from 34 patients with acute myocarditis and 17 control patients with congenital heart disease or hypertrophic cardiomyopathy were tested by PCR for adenovirus and enterovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/16\">",
"     16",
"    </a>",
"    ]. Although enteroviruses have been implicated as the major etiology of viral myocarditis, adenovirus DNA was detected more commonly (15 samples) than enterovirus DNA (eight samples). All control samples were negative. In another report, PCR was used to make a diagnosis of intrauterine adenovirus myocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22986?source=see_link&amp;anchor=H18#H18\">",
"     \"Etiology and pathogenesis of myocarditis\", section on 'Adenovirus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical manifestations and diagnosis of myocarditis in adults\", section on 'Determination of specific etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical manifestations and diagnosis of myocarditis in children\", section on 'Endomyocardial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, detection of adenovirus by PCR in heart biopsies of cardiac transplant recipients may correlate with increased graft loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histopathologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive diagnosis of adenovirus disease may require tissue biopsy. Specimens should be obtained for both pathology and viral culture or PCR, because routine histopathology may be nonspecific, especially in the early stages of infections.",
"   </p>",
"   <p>",
"    Adenoviruses can cause characteristic intranuclear inclusions (",
"    <a class=\"graphic graphic_picture graphicRef56007 \" href=\"mobipreview.htm?28/43/29364\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/19\">",
"     19",
"    </a>",
"    ]. Early post-infection, cells may display small eosinophilic inclusions. During the later stages of infection, basophilic inclusions appear, which initially may be surrounded by a clear halo within the nucleus. When these intranuclear inclusions enlarge and obscure the nuclear membrane, the cells are referred to as \"smudge\" cells (",
"    <a class=\"graphic graphic_picture graphicRef56007 \" href=\"mobipreview.htm?28/43/29364\">",
"     picture 1",
"    </a>",
"    ). Occasionally, adenovirus inclusions may be confused with cytomegalovirus (CMV) inclusions, but unlike CMV, adenoviruses cause neither intracytoplasmic inclusions nor multinucleated cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If routine histopathology is nondiagnostic and viral culture of tissue is negative (or not done), more specialized tests may be performed on tissue samples. Electron microscopy can be used to detect the characteristic icosahedral virions that typically form large paracrystalline aggregates with the nuclei of infected cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/21\">",
"     21",
"    </a>",
"    ]. Adenovirus-specific immunohistochemical assays and in situ DNA assays are also available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recent infection may be documented by assay of paired acute and convalescent sera for adenovirus-specific antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/24\">",
"     24",
"    </a>",
"    ]. It is important to document a fourfold or greater rise in antibody titer because there is a high prevalence of anti-adenovirus antibodies in the general population, and there are numerous cross-reactions between related serotypes.",
"   </p>",
"   <p>",
"    Commercially available enzyme immunoassays (EIAs) and complement fixation assays measure adenovirus-specific anti-hexon antibodies, but do not provide information about the serotype. In contrast, detection of hemagglutination inhibition antibodies or neutralizing antibodies is more sensitive and is serotype-specific. These assays are primarily performed in reference laboratories and are best interpreted when the patient's sera is tested against the patient's own isolate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18818704\">",
"    <span class=\"h2\">",
"     Serotyping and genotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;After recovery of a clinical isolate on tissue culture, further evaluation can be performed by serotype analysis in a reference virology laboratory. Certain serotypes are associated with distinct clinical manifestations (",
"    <a class=\"graphic graphic_table graphicRef63104 \" href=\"mobipreview.htm?34/24/35211\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serotype is determined by first grouping the isolate by hemagglutination pattern with rat and rhesus red blood cells. Then, hemagglutination inhibition",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serum neutralization assays can be performed using a selected panel of type-specific sera. Genotyping can also be accomplished by PCR and sequencing, which is substantially faster than the traditional serotyping methods, although it is not widely available. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Polymerase chain reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18818726\">",
"    <span class=\"h2\">",
"     Restriction endonuclease analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restriction endonuclease (RE) analysis can distinguish between different clinical isolates of the same serotype. RE analysis is useful for epidemiologic analysis, eg, during outbreaks of adenovirus infection. As an example, RE was used to analyze isolates obtained during an outbreak of EKC caused by adenovirus serotype 8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/25\">",
"     25",
"    </a>",
"    ]. In this epidemic, cases occurred simultaneously in two childcare centers, followed by prolonged outbreaks within the community and among staff at the local hospital. RE analysis of the genomes of five isolates revealed they were identical and distinct from the prototype adenovirus serotype 8, supporting the conclusion that the cases in the larger outbreak were connected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS OF CHOICE FOR DIFFERENT ADENOVIRUS SYNDROMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic test of choice varies depending upon the clinical scenario (",
"    <a class=\"graphic graphic_table graphicRef81573 \" href=\"mobipreview.htm?35/63/36859\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Upper respiratory illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses should be suspected as one of the causes of febrile illnesses with respiratory symptoms in infants and young children. Adenoviruses are a common cause of tonsillitis in young children. Conjunctivitis accompanied by pharyngeal symptoms, known as pharyngoconjunctival fever, is a characteristic, though less frequent, adenovirus syndrome. Adenoviruses are also implicated in outbreaks of febrile respiratory disease in summer camps and swimming pools. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\", section on 'Respiratory tract'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When warranted, such as during an epidemic, diagnosis can be confirmed by viral culture of the nasopharynx or throat. If viral culture is unavailable, the specimen may be tested with the less sensitive adenovirus-specific enzyme-linked immunosorbent assay.",
"   </p>",
"   <p>",
"    The differential diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rhinovirus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19383?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Influenza (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Laboratory diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link\">",
"       \"Diagnosis of seasonal influenza in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Respiratory syncytial virus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link&amp;anchor=H27#H27\">",
"       \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Laboratory diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parainfluenza (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=see_link&amp;anchor=H11#H11\">",
"       \"Parainfluenza viruses in children\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=see_link&amp;anchor=H14#H14\">",
"       \"Parainfluenza viruses in adults\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Epidemic keratoconjunctivitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses are the most common cause of epidemic keratoconjunctivitis (EKC), a syndrome characterized by eye pain and inflammation, fever, and preauricular lymphadenopathy. EKC often occurs in outbreaks. It is best to obtain conjunctival swabs for both viral culture and adenovirus-specific enzyme-linked immunosorbent assay or polymerase chain reaction (PCR) assay to make a diagnosis of EKC, since subgroup D isolates, which are frequently implicated, can take two to four weeks to grow in tissue culture.",
"   </p>",
"   <p>",
"    The differential diagnosis includes bacterial conjunctivitis as well as other viral pathogens such as enteroviruses and herpes simplex virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=see_link&amp;anchor=H4#H4\">",
"     \"Conjunctivitis\", section on 'Bacterial conjunctivitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of enterovirus and parechovirus infections\", section on 'Ocular infections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Keratitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses are an important etiology of fever and interstitial pulmonary infiltrates in infants and children. Although uncommon in adults, there have been well-described outbreaks of adenovirus pneumonia among military recruits and among adults in chronic care facilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. A diagnosis can be made by viral culture, direct antigen assay, or polymerase chain reaction (PCR) assay on a nasopharyngeal aspirate or swab, throat swab, sputum sample, or bronchoalveolar lavage fluid.",
"   </p>",
"   <p>",
"    Multiplex PCR assays that detect a panel of respiratory viruses including adenovirus from nasopharyngeal specimens are especially useful for evaluation of hospitalized patients with suspected respiratory viral pneumonia or other influenza-like illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory syncytial virus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=see_link&amp;anchor=H27#H27\">",
"       \"Respiratory syncytial virus infection: Clinical features and diagnosis\", section on 'Laboratory diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Influenza (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link&amp;anchor=H1018262491#H1018262491\">",
"       \"Diagnosis of seasonal influenza in adults\", section on 'Approach to diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=see_link&amp;anchor=H19#H19\">",
"       \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Laboratory diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parainfluenza (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=see_link&amp;anchor=H14#H14\">",
"       \"Parainfluenza viruses in adults\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=see_link&amp;anchor=H11#H11\">",
"       \"Parainfluenza viruses in children\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Human metapneumovirus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=see_link&amp;anchor=H8#H8\">",
"       \"Human metapneumovirus infections\", section on 'Clinical manifestations'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diarrhea in young children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although rotavirus is the more common pathogen, enteric adenoviruses (types 40 or 41) can cause a prolonged diarrheal syndrome in infants, especially in the setting of clusters, eg, in day care centers or as a nosocomial infection. The test of choice is an adenovirus-specific enzyme-linked immunosorbent assay on a stool specimen, because enteric adenoviruses do not grow on routine tissue culture. Symptoms are self-limited and treatment is supportive. Strict infection control methods in day care centers may help to prevent transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Infections in immunocompromised hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses cause a wide range of clinical syndromes in immunocompromised hosts, including pneumonia, hemorrhagic",
"    <span class=\"nowrap\">",
"     cystitis/nephritis,",
"    </span>",
"    colitis, hepatitis, and encephalitis. Adenovirus infections most commonly occur in immunocompromised children, resulting from either reactivation of latent infection or primary infection. Because adenoviruses may be shed asymptomatically in throat, stool, or urine, it is often necessary to obtain tissue to document disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link&amp;anchor=H21#H21\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\", section on 'Infections in immunocompromised hosts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adenoviruses may cause severe, sometimes fatal, disease in hematopoietic stem cell transplant recipients. Quantitative PCR in blood has been used to identify hematopoietic stem cell transplant recipients at risk for dissemination and to help monitor the response to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/10-12,30\">",
"     10-12,30",
"    </a>",
"    ]. After hematopoietic stem cell transplantation, recovery of T cell function and adenovirus-specific T cells have been associated with a favorable outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Recipients of T cell depleted grafts or those with graft-versus-host disease (GVHD) are at highest risk of disease and mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The specific diagnosis of adenovirus infection in immunocompromised patients may require the use of multiple diagnostic modalities on various specimens. Viral culture, direct antigen assays, or PCR of upper nasopharyngeal, throat, urine, and stool or rectal samples will detect viral shedding. Results should be interpreted in the context of clinical manifestations consistent with adenovirus infection. In addition, testing of affected sites (including lower respiratory tract secretions collected by tracheal aspirate or bronchoalveolar lavage in patients with pneumonia; urine in patients with hemorrhagic cystitis; CSF in patients with central nervous system involvement; and tissue biopsy in patients with pneumonia, colitis, nephritis, or hepatitis) may be needed to diagnose adenovirus infection. Quantitative PCR of blood is helpful to establish a diagnosis, evaluate prognosis, and monitor response to antiviral therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. In one study, high viral loads measured in stool by quantitative PCR were detected days to weeks prior to onset of viremia (median 11 days) in pediatric allogeneic stem cell recipients, whereas low stool viral loads were not associated with viremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As has been shown for cytomegalovirus (CMV) infections, early identification of patients at risk for adenovirus disease by monitoring for viremia by PCR is beneficial; thus, some centers have adopted routine weekly surveillance measures for pediatric recipients of allogeneic hematopoietic stem cell transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/10,34,35\">",
"     10,34,35",
"    </a>",
"    ]. If viremia is detected, then patients should be carefully evaluated for evidence of disease, such as pneumonia, hepatitis, cystitis, and colitis, and specimens should be obtained for adenovirus testing from affected sites. Although viremia is self-limited in some patients, a rising viral load has been associated with invasive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In contrast to CMV, the benefit of preemptive treatment based on viremia alone has not been established for adenovirus and is not currently recommended because of the toxicity of the most commonly used antiviral agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    . Further clinical studies are also needed to identify effective and safe treatments. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most adenovirus infections are self-limited and treatment is supportive. However, adenovirus infections can be fatal in neonates and immunocompromised hosts, and rarely in healthy children and adults. Given the potential toxicities of the therapy for adenovirus infections (especially nephrotoxicity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    ), we recommend that an infectious diseases specialist be consulted when treatment is being considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antiviral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral therapy is generally reserved for immunocompromised hosts and patients with severe disease.",
"   </p>",
"   <p>",
"    There have been no controlled trials demonstrating benefit for any antiviral agent in human adenoviral disease. The antiviral agent most commonly used for adenoviral infection is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , which is currently approved for the treatment of cytomegalovirus (CMV) infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    appears more active against adenovirus in vitro than other antiviral drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/36\">",
"     36",
"    </a>",
"    ], and also appears active in vivo as demonstrated by reductions in adenoviral load measured by real-time polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Published data on the efficacy of cidofovir for adenovirus infection in humans are limited to case reports and small nonrandomized studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/11,12,37-40\">",
"     11,12,37-40",
"    </a>",
"    ]. In hematopoietic stem cell and lung transplant recipients, cidofovir therapy has been associated with clinical improvement and a suggestion of increased survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/12,37-39\">",
"     12,37-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , the mortality in patients with invasive adenoviral disease following allogeneic stem cell transplantation varied from 25 to 75 percent in different series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], with the higher rates being described in patients with pneumonia and disseminated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/12,42,43\">",
"     12,42,43",
"    </a>",
"    ]. In contrast, the mortality rate from adenoviral disease was only 19 percent in a review of 70 published cases of definite or probable adenovirus infection treated with two or more doses of cidofovir; most of these patients were severely immunocompromised (eg, graft-versus-host disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    T cell-depleted allografts) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/12\">",
"     12",
"    </a>",
"    ]. However, in a report of 11 severely immunocompromised patients with adenovirus infection who were treated with cidofovir, five died including all three with pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/44\">",
"     44",
"    </a>",
"    ]. Therefore, although early diagnosis and treatment of adenovirus infections in this patient population may improve outcomes, lymphocyte reconstitution also appears crucial for recovery from disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrotoxicity is a major dose-limiting factor for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    . As a result, doses of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day or three times per week instead of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    weekly have been used in an attempt to reduce this toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/39\">",
"     39",
"    </a>",
"    ]. Further clinical studies are needed to assess the efficacy and the nephrotoxicity of cidofovir in various dosing schedules. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5121686\">",
"    <span class=\"h3\">",
"     Lipid-ester derivatives of cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A still experimental series of oral lipid-ester derivatives of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    exhibit enhanced in vitro activity against adenoviruses compared with cidofovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/46\">",
"     46",
"    </a>",
"    ]. In one study, treatment with the cidofovir prodrug CMX001 rescued hamsters from a lethal challenge with adenovirus serotype 5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/47\">",
"     47",
"    </a>",
"    ]. Disseminated adenovirus disease was also successfully treated with CMX001 in one human pediatric stem cell transplant recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/48\">",
"     48",
"    </a>",
"    ]. The oral cidofovir prodrugs may have a lower potential for nephrotoxicity than cidofovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    has limited activity against adenovirus in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/50\">",
"     50",
"    </a>",
"    ] and neither",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    nor vidarabine has consistent activity against adenovirus in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/51\">",
"     51",
"    </a>",
"    ]. There are case reports of patients responding to treatment with each of these agents, but the evidence for efficacy in vivo remains anecdotal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Immunotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence for the use of immunotherapy in the treatment of adenovirus disease in immunocompromised patients. Pooled intravenous immune globulin (IVIG) contains high levels of neutralizing antibodies against common lower adenoviral serotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/55\">",
"     55",
"    </a>",
"    ] and is commonly used as adjunctive therapy in immunocompromised patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/12,32\">",
"     12,32",
"    </a>",
"    ]. In one case, a child with severe combined immunodeficiency (SCID) and a severe adenovirus serotype 7 pneumonia responded rapidly to therapy with high dose IVIG containing a high titer of neutralizing antibody against serotype 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/56\">",
"     56",
"    </a>",
"    ]. In a murine model of mouse adenovirus infection, passive transfer of adenovirus-specific IgG resulted in a marked delay in mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T cell immunity is critical for recovery from adenovirus infection following hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/58\">",
"     58",
"    </a>",
"    ]. Pilot studies of adoptive transfer of T cell immunity have been performed in children with adenovirus infection after stem cell transplantation. In one study, virus-specific donor T cells were isolated and infused into nine children with systemic adenovirus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/59\">",
"     59",
"    </a>",
"    ]. In vivo expansion of adenovirus-specific T cells was demonstrated and viral clearance was attained in five of six evaluable patients. In one patient, adoptive T cell transfer led to exacerbation of preexisting graft-versus-host disease.",
"   </p>",
"   <p>",
"    In another study, pediatric stem cell transplant recipients were treated with donor lymphocytes stimulated in vitro with adenovirus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/60\">",
"     60",
"    </a>",
"    ]. Reductions in viral loads were documented in three of three patients with active infection, and clinical improvement was documented in one patient with adenovirus pneumonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination and infection control measures have been applied in certain settings to prevent adenovirus infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Live oral enteric-coated vaccines directed against adenovirus serotypes 4 and 7 had been used for years in military recruits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/61\">",
"     61",
"    </a>",
"    ]. They are safe and effective in the prevention of epidemics of acute respiratory disease in military training camps. In the 1990s, the manufacturer of the vaccines stopped production. Subsequently, new outbreaks of adenovirus serotypes 4 and 7 disease in training camps have been described, including several fatalities, underscoring the continued need for the vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. In 2011, a new live, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9524?source=see_link\">",
"     adenovirus vaccine",
"    </a>",
"    against adenovirus serotypes 4 and 7 was approved for use in United States military personnel aged 17 through 50 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The emergence of adenovirus serotype 14, a subtype B2 adenovirus, in military recruits may also be related to the discontinuation of the adenovirus serotypes 4 and 7 vaccine program, since heterotypic antibodies to adenovirus 14 develop following adenovirus 7 immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/64,67,68\">",
"     64,67,68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\", section on 'Adenovirus 14'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Infection control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoviruses can stay viable for prolonged periods on environmental surfaces such as sinks and hand towels, and they are not susceptible to some commonly used disinfectants such as alcohol and ether [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/69\">",
"     69",
"    </a>",
"    ]. Therefore, decontamination of environmental surfaces and instruments may be difficult and requires specific agents such as chlorine, formaldehyde, or heat. Outbreaks of pharyngoconjunctival fever from swimming pool exposure have usually been associated with inadequate water chlorination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adenoviruses can cause significant nosocomial infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. In one report, 126 (7 percent) of 1870 ophthalmology clinic patients developed epidemic keratoconjunctivitis (EKC) due to adenovirus serotype 8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/71\">",
"     71",
"    </a>",
"    ]. Transmission was attributed to inadequate disinfection of instruments and to finger-to-eye transmission by health care workers. Of note, handwashing did not reliably remove adenoviruses from contaminated fingers. The recommendations from this study included using gloves to examine patients with EKC and decontaminating instruments with 10 percent bleach.",
"   </p>",
"   <p>",
"    In another report, an epidemic of adenovirus serotype 7 occurred in a neonatal intensive care nursery resulting in the death of two patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/72\">",
"     72",
"    </a>",
"    ]. Symptomatic infection occurred in 9 patients, 10 staff, and 3 parents. The outbreak was controlled by cohorting patients, using gloves, gowns, and goggles, and excluding symptomatic staff from the unit.",
"   </p>",
"   <p>",
"    Prolonged infection control measures may be necessary to ensure elimination of adenovirus following a nosocomial outbreak [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/74\">",
"     74",
"    </a>",
"    ]. The Committee on Infectious Diseases of the American Academy of Pediatrics recommends the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?36/40/37513/abstract/75\">",
"     75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with conjunctivitis and for patients with gastroenteritis who are incontinent or in diapers, contact precautions should be maintained for the duration of the illness. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"       \"General principles of infection control\", section on 'Contact precautions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For those with respiratory tract infections, contact and droplet precautions are recommended for the duration of the hospitalization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"       \"General principles of infection control\", section on 'Contact precautions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H12#H12\">",
"       \"General principles of infection control\", section on 'Droplet precautions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Disposable gloves and assiduous hand washing should be used when caring for infected patients.",
"     </li>",
"     <li>",
"      Healthcare personnel with known or suspected adenoviral conjunctivitis should avoid direct patient contact for 14 days after the onset of disease in their second eye.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who participate in group childcare, particularly during the first two years of life, are at increased risk for adenoviral respiratory tract infections and gastroenteritis. Specific preventive measures in this setting have not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13426?source=see_link\">",
"       \"Patient information: Adenovirus infections (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12480845\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical criteria are not sufficient to accurately diagnose adenovirus infection. Laboratory confirmation of adenovirus infection should be performed if there is suspicion of this diagnosis and confirmation would be helpful in making decisions about antiviral therapy, excluding other treatable infections, establishing a prognosis, and continuing infection control measures when appropriate. (See",
"      <a class=\"local\" href=\"#H18818874\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic tests for adenovirus include viral culture, viral antigen assays (adenovirus-specific enzyme-linked immunosorbent assay or immunofluorescence assay), polymerase chain reaction assays, histopathologic studies, and serology (",
"      <a class=\"graphic graphic_table graphicRef59727 \" href=\"mobipreview.htm?5/48/5901\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnostic tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic test of choice varies depending upon the clinical scenario (",
"      <a class=\"graphic graphic_table graphicRef81573 \" href=\"mobipreview.htm?35/63/36859\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic tests of choice for different adenovirus syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adenovirus infections are self-limited and treatment is supportive. Antiviral therapy generally is reserved for immunocompromised hosts and patients with severe disease, but controlled clinical trials have not been performed. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Antiviral agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When treatment is indicated,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"       cidofovir",
"      </a>",
"      has been the antiviral agent most frequently used. Nephrotoxicity is a major dose-limiting factor for cidofovir. We recommend consultation with an infectious diseases specialist when treatment is being considered. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Cidofovir'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pooled intravenous immune globulin has been used as adjunctive therapy in immunocompromised patients, but controlled clinical trials have not been performed. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Immunotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prevention of adenovirus infection requires decontamination of environmental surfaces and instruments with agents such as chlorine, formaldehyde, or heat; adenoviruses are not susceptible to alcohol, ether, or many other commonly used disinfectants. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hospitalized patients with gastrointestinal, conjunctival, and respiratory adenovirus infection should be placed on contact precautions; those with respiratory infection should also be placed on droplet precautions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H11#H11\">",
"       \"General principles of infection control\", section on 'Contact precautions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=see_link&amp;anchor=H12#H12\">",
"       \"General principles of infection control\", section on 'Droplet precautions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/1\">",
"      Levent F, Greer JM, Snider M, Demmler-Harrison GJ. Performance of a new immunochromatographic assay for detection of adenoviruses in children. J Clin Virol 2009; 44:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/2\">",
"      Raboni SM, Siqueira MM, Portes SR, Pasquini R. Comparison of PCR, enzyme immunoassay and conventional culture for adenovirus detection in bone marrow transplant patients with hemorrhagic cystitis. J Clin Virol 2003; 27:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/3\">",
"      Herrmann JE, Perron-Henry DM, Blacklow NR. Antigen detection with monoclonal antibodies for the diagnosis of adenovirus gastroenteritis. J Infect Dis 1987; 155:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/4\">",
"      Wiley LA, Roba LA, Kowalski RP, et al. A 5-year evaluation of the adenoclone test for the rapid diagnosis of adenovirus from conjunctival swabs. Cornea 1996; 15:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/5\">",
"      Allard A, Albinsson B, Wadell G. Detection of adenoviruses in stools from healthy persons and patients with diarrhea by two-step polymerase chain reaction. J Med Virol 1992; 37:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/6\">",
"      Claas EC, Schilham MW, de Brouwer CS, et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol 2005; 43:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/7\">",
"      Damen M, Minnaar R, Glasius P, et al. Real-time PCR with an internal control for detection of all known human adenovirus serotypes. J Clin Microbiol 2008; 46:3997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/8\">",
"      Heim A, Ebnet C, Harste G, Pring-Akerblom P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 2003; 70:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/9\">",
"      Echavarria M, Forman M, van Tol MJ, et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/10\">",
"      Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/11\">",
"      Leruez-Ville M, Minard V, Lacaille F, et al. Real-time blood plasma polymerase chain reaction for management of disseminated adenovirus infection. Clin Infect Dis 2004; 38:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/12\">",
"      Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/13\">",
"      Lankester AC, Heemskerk B, Claas EC, et al. Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection. Clin Infect Dis 2004; 38:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/14\">",
"      Lankester AC, van Tol MJ, Claas EC, et al. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin Infect Dis 2002; 34:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/15\">",
"      Gray GC, McCarthy T, Lebeck MG, et al. Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006. Clin Infect Dis 2007; 45:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/16\">",
"      Martin AB, Webber S, Fricker FJ, et al. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 1994; 90:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/17\">",
"      Towbin JA, Griffin LD, Martin AB, et al. Intrauterine adenoviral myocarditis presenting as nonimmune hydrops fetalis: diagnosis by polymerase chain reaction. Pediatr Infect Dis J 1994; 13:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/18\">",
"      Shirali GS, Ni J, Chinnock RE, et al. Association of viral genome with graft loss in children after cardiac transplantation. N Engl J Med 2001; 344:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/19\">",
"      Becroft DM. Histopathology of fatal adenovirus infection of the respiratory tract in young children. J Clin Pathol 1967; 20:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/20\">",
"      Landry ML, Fong CK, Neddermann K, et al. Disseminated adenovirus infection in an immunocompromised host. Pitfalls in diagnosis. Am J Med 1987; 83:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/21\">",
"      Pinkerton H, Carroll S. Fatal adenovirus pneumonia in infants. Correlation of histologic and electron microscopic observations. Am J Pathol 1971; 65:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/22\">",
"      Matsuoka T, Naito T, Kubota Y, et al. Disseminated adenovirus (type 19) infection in a neonate. Rapid detection of the infection by immunofluorescence. Acta Paediatr Scand 1990; 79:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/23\">",
"      Wu TC, Kanayama MD, Hruban RH, et al. Virus-associated RNAs (VA-I and VA-II). An efficient target for the detection of adenovirus infections by in situ hybridization. Am J Pathol 1992; 140:991.",
"     </a>",
"    </li>",
"    <li>",
"     Horwitz MS. Adenoviruses. In: Fields Virology, 3rd ed, Fields BN, Knipe DM, Howley PM (Eds), Lippincott-Raven Publishers, Philadelphia 1996. p.2160.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/25\">",
"      McMinn PC, Stewart J, Burrell CJ. A community outbreak of epidemic keratoconjunctivitis in central Australia due to adenovirus type 8. J Infect Dis 1991; 164:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/26\">",
"      Klinger JR, Sanchez MP, Curtin LA, et al. Multiple cases of life-threatening adenovirus pneumonia in a mental health care center. Am J Respir Crit Care Med 1998; 157:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/27\">",
"      Yang E, Rubin BK. \"Childhood\" viruses as a cause of pneumonia in adults. Semin Respir Infect 1995; 10:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/28\">",
"      Lee WM, Grindle K, Pappas T, et al. High-throughput, sensitive, and accurate multiplex PCR-microsphere flow cytometry system for large-scale comprehensive detection of respiratory viruses. J Clin Microbiol 2007; 45:2626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/29\">",
"      Caliendo AM. Multiplex PCR and emerging technologies for the detection of respiratory pathogens. Clin Infect Dis 2011; 52 Suppl 4:S326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/30\">",
"      Erard V, Huang ML, Ferrenberg J, et al. Quantitative real-time polymerase chain reaction for detection of adenovirus after T cell-replete hematopoietic cell transplantation: viral load as a marker for invasive disease. Clin Infect Dis 2007; 45:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/31\">",
"      Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/32\">",
"      Myers GD, Bollard CM, Wu MF, et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 39:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/33\">",
"      Lion T, Kosulin K, Landlinger C, et al. Monitoring of adenovirus load in stool by real-time PCR permits early detection of impending invasive infection in patients after allogeneic stem cell transplantation. Leukemia 2010; 24:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/34\">",
"      Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/35\">",
"      Sivaprakasam P, Carr TF, Coussons M, et al. Improved outcome from invasive adenovirus infection in pediatric patients after hemopoietic stem cell transplantation using intensive clinical surveillance and early intervention. J Pediatr Hematol Oncol 2007; 29:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/36\">",
"      Kodama E, Shigeta S, Suzuki T, De Clercq E. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Antiviral Res 1996; 31:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/37\">",
"      Legrand F, Berrebi D, Houhou N, et al. Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children. Bone Marrow Transplant 2001; 27:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/38\">",
"      Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2003; 31:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/39\">",
"      Doan ML, Mallory GB, Kaplan SL, et al. Treatment of adenovirus pneumonia with cidofovir in pediatric lung transplant recipients. J Heart Lung Transplant 2007; 26:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/40\">",
"      Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/41\">",
"      Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/42\">",
"      La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis 2001; 32:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/43\">",
"      Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/44\">",
"      Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. Transpl Infect Dis 2007; 9:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/45\">",
"      Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis 2005; 191:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/46\">",
"      Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/47\">",
"      Toth K, Spencer JF, Dhar D, et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A 2008; 105:7293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/48\">",
"      Paolino K, Sande J, Perez E, et al. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J Clin Virol 2011; 50:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/49\">",
"      Ciesla SL, Trahan J, Wan WB, et al. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003; 59:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/50\">",
"      Taylor DL, Jeffries DJ, Taylor-Robinson D et al. The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (DHPG. FEMS Microbiol Lett 1988; 49:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/51\">",
"      Baba M, Mori S, Shigeta S, De Clercq E. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2'-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother 1987; 31:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/52\">",
"      Sabroe I, McHale J, Tait DR, et al. Treatment of adenoviral pneumonitis with intravenous ribavirin and immunoglobulin. Thorax 1995; 50:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/53\">",
"      Hromas R, Clark C, Blanke C, et al. Failure of ribavirin to clear adenovirus infections in T cell-depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/54\">",
"      Kawakami M, Ueda S, Maeda T, et al. Vidarabine therapy for virus-associated cystitis after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/55\">",
"      Flomenberg PR, Chen M, Munk G, Horwitz MS. Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. J Infect Dis 1987; 155:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/56\">",
"      Dagan R, Schwartz RH, Insel RA, Menegus MA. Severe diffuse adenovirus 7a pneumonia in a child with combined immunodeficiency: possible therapeutic effect of human immune serum globulin containing specific neutralizing antibody. Pediatr Infect Dis 1984; 3:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/57\">",
"      Lenaerts L, Kelchtermans H, Geboes L, et al. Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection. Antimicrob Agents Chemother 2008; 52:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/58\">",
"      Hromas R, Cornetta K, Srour E, et al. Donor leukocyte infusion as therapy of life-threatening adenoviral infections after T-cell-depleted bone marrow transplantation. Blood 1994; 84:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/59\">",
"      Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/60\">",
"      Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/61\">",
"      Top FH Jr, Dudding BA, Russell PK, Buescher EL. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol 1971; 94:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/62\">",
"      Barraza EM, Ludwig SL, Gaydos JC, Brundage JF. Reemergence of adenovirus type 4 acute respiratory disease in military trainees: report of an outbreak during a lapse in vaccination. J Infect Dis 1999; 179:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/63\">",
"      Centers for Disease Control and Prevention (CDC). Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/64\">",
"      Metzgar D, Osuna M, Kajon AE, et al. Abrupt emergence of diverse species B adenoviruses at US military recruit training centers. J Infect Dis 2007; 196:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/65\">",
"      Lyons A, Longfield J, Kuschner R, et al. A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 2008; 26:2890.",
"     </a>",
"    </li>",
"    <li>",
"     Adenovirus type 4 and type 7 live oral vaccine prescribing information. file://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM247515.pdf (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/67\">",
"      Binn LN, Sanchez JL, Gaydos JC. Emergence of adenovirus type 14 in US military recruits--a new challenge. J Infect Dis 2007; 196:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/68\">",
"      PRINS A. Studies of the significance of the recall phenomenon in the antibody response to adenovirus vaccine and infection. J Immunol 1960; 84:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/69\">",
"      Buehler JW, Finton RJ, Goodman RA, et al. Epidemic keratoconjunctivitis: report of an outbreak in an ophthalmology practice and recommendations for prevention. Infect Control 1984; 5:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/70\">",
"      D'Angelo LJ, Hierholzer JC, Keenlyside RA, et al. Pharyngoconjunctival fever caused by adenovirus type 4: report of a swimming pool-related outbreak with recovery of virus from pool water. J Infect Dis 1979; 140:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/71\">",
"      Jernigan JA, Lowry BS, Hayden FG, et al. Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: risk factors and control. J Infect Dis 1993; 167:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/72\">",
"      Finn A, Anday E, Talbot GH. An epidemic of adenovirus 7a infection in a neonatal nursery: course, morbidity, and management. Infect Control Hosp Epidemiol 1988; 9:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/73\">",
"      Faden H, Wynn RJ, Campagna L, Ryan RM. Outbreak of adenovirus type 30 in a neonatal intensive care unit. J Pediatr 2005; 146:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?36/40/37513/abstract/74\">",
"      Piedra PA. Adenovirus in the neonatal intensive care unit: formidable, forgotten foe. J Pediatr 2005; 146:447.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Adenovirus infections. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.220.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8348 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37513=[""].join("\n");
var outline_f36_40_37513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12480845\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18818874\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Viral culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Viral antigen assay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Polymerase chain reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histopathologic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18818704\">",
"      Serotyping and genotyping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18818726\">",
"      Restriction endonuclease analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC TESTS OF CHOICE FOR DIFFERENT ADENOVIRUS SYNDROMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Upper respiratory illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Epidemic keratoconjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diarrhea in young children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Infections in immunocompromised hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antiviral agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5121686\">",
"      - Lipid-ester derivatives of cidofovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12480845\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8348\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8348|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?28/43/29364\" title=\"picture 1\">",
"      Adenovirus inclusions liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8348|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/48/5901\" title=\"table 1\">",
"      Diagnostic tests for adenovirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/24/35211\" title=\"table 2\">",
"      Adenovirus serotypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/63/36859\" title=\"table 3\">",
"      Approach to diagnostic testing for adenovirus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/49/34585?source=related_link\">",
"      Clinical manifestations and diagnosis of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/16/26889?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=related_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/59/19383?source=related_link\">",
"      Epidemiology, clinical manifestations, and pathogenesis of rhinovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/28/22986?source=related_link\">",
"      Etiology and pathogenesis of myocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/33/33304?source=related_link\">",
"      Human metapneumovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/617?source=related_link\">",
"      Parainfluenza viruses in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36808?source=related_link\">",
"      Parainfluenza viruses in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/7/13426?source=related_link\">",
"      Patient information: Adenovirus infections (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f36_40_37514="Gross and light microscopic features of plaque rupture";
var content_f36_40_37514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Gross and light microscopic features of plaque rupture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 588px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross and light microscopic features of plaque rupture.",
"    <br>",
"     (A) Gross photograph of a coronary artery in cross-section showing site of plaque rupture (arrow) with an underlying necrotic core (NC) and luminal thrombus (Th).",
"     <br>",
"      (B) Histologic section of the artery in A shows the rupture site (arrows), necrotic core (NC), and luminal thrombus (Th) (Movat pentachrome, x20).",
"      <br>",
"       (C) Higher-power view of the fibrous cap shows disruption (arrow), where there is communication of the luminal thrombus (Th) with the underlying necrotic core (NC) (x200).",
"       <br>",
"        (D) Higher-power view of the thin fibrous cap shows a paucity of smooth muscle cells (&alpha;-actin, brown reaction product, x200).",
"        <br>",
"         (E, F) The fibrous cap is heavily infiltrated by macrophages and T-lymphocytes (CD68 and CD45Ro, respectively) (x200).",
"         <br>",
"          (G) The strong expression of HLA-DR (an antigen expressed in activated cells), particularly in macrophages and T-cells of the fibrous cap.",
"          <div class=\"footnotes\">",
"          </div>",
"          <div class=\"reference\">",
"           Reproduced with permission from: Farb A, Burke AP, Tang AL, et al. Coronary Plaque Erosion Without Rupture Into a Lipid Core: A Frequent Cause of Coronary Thrombosis in Sudden Coronary Death. Circulation 1996; 93:1354. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"          </div>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37514=[""].join("\n");
var outline_f36_40_37514=null;
var title_f36_40_37515="PFPS sample phys ther Rx";
var content_f36_40_37515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sample physical therapy prescription for PFPS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Physical therapy prescription",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Dx:",
"       </strong>",
"       PFPS (Left / Right / Bilateral) ICD9 (719.46)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Rx: (NOTE: the exercises listed below are examples only and are not intended to limit the physical therapist.)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Hip abduction strengthening: (eg, lateral steps with elastic band around knees (monster walks): 1 minute x 3 sets; hip hikes: 2 sets of 20 repetitions each side; clamshells (hip abduction with rubber band above knees while laying on side): 3 sets of 12 repetitions each side).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Close chain quadriceps strengthening: (eg, terminal knee extensions with elastic band 3 sets of 15 reps; leg presses 3 sets of 10 repetitions; semi squats 3 sets of 10 repetitions).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3. Pelvic stability training: (eg, standing single leg hip flexion, extension, abduction and adduction with elastic band, 3 sets of 12 repetitions; single leg proprioceptive training; other balance training).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Hamstring, quadriceps, and iliotibial band flexibility training.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. Please instruct in home exercise program.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6. No other treatment modalities other than post-therapy ice prn (unless specifically requested and reviewed with prescribing clinician).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Frequency:",
"       </strong>",
"       2 visits of 45 minutes per week for 6 weeks. (Reassess at 6 weeks or earlier as needed by insurance carrier to represcribe therapy).",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37515=[""].join("\n");
var outline_f36_40_37515=null;
var title_f36_40_37516="Education at subsequent visits";
var content_f36_40_37516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delivery of asthma education by clinicians during patient care visits: recommendations for all subsequent visits",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Assessment questions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Focus on:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Expectations of visit",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Goals of treatment",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Quality of life",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask relevant questions from previous visit and also ask:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"How have you tried to control things that make your asthma worse?\"",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            \"Please show me how you use your inhaled medication.\"",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Information",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review in simple language:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Review and reinforce all:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Educational messages",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Environmental control strategeis at home, work, or school",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Review and interpret from daily diary:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Peak flow measures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            Symptom scores",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Skills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Teach or review and demonstrate:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Inhaler/spacer/holding chamber techique.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Peak flow monitoring technique.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Use of daily self-management plan. Review and adjust as needed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Review use of action plan. Confirm that patient knows what to do if",
"asthma gets worse. Periodically review and adjust written action plan.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37516=[""].join("\n");
var outline_f36_40_37516=null;
var title_f36_40_37517="View through a rigid bronchoscope - epiglottis to trachea";
var content_f36_40_37517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/51963/rgintbii_conv.mp4?title=View+through+a+rigid+bronchoscope+-+epiglottis+to+trachea\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rigid broncoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Video shows the view through a rigid bronchoscope as it is passed from the epiglottis to the trachea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD and Praveen Mathur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37517=[""].join("\n");
var outline_f36_40_37517=null;
var title_f36_40_37518="Pelvic trauma algorithm";
var content_f36_40_37518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Pelvic trauma algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 328px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DPA: diagnostic peritoneal aspirate; FAST: focused assessment with sonography for trauma; MDCT: multidetector computed tomography.",
"     <br>",
"      * DPA indicated when the cause of hemodynamic instability is unclear.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Treatment options vary with local resources.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37518=[""].join("\n");
var outline_f36_40_37518=null;
var title_f36_40_37519="Manual vertical traction";
var content_f36_40_37519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manual cervical traction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The head is grasped at the mid jaw and at the occiput. The patient is asked to relax the neck muscles. Gentle vertical traction is performed to assess the effect on the patient's neck pain, stiffness, and, when present, radicular pain. Relief of pain with this maneuver provides additional support for the diagnosis of radiculopathy and suggests that the patient may respond to therapeutic home traction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f36_40_37519=[""].join("\n");
var outline_f36_40_37519=null;
